Military Working Dog Whole Blood Product or Substitute - SBIR DHA26BZ01-NV001

Disclaimer:
This topic was temporarily posted by the Department of War SBIR Program on March 2nd 2026 and removed the following day.
We believe this topic is planned to be released once the SBIR program is reauthorized; however, this topic may ultimately be modified or withdrawn.

Sign up below to be notified as soon as this topic is released again. In the meantime, we’d recommend you start planning to respond if within your capabilities.

Funding Amount:

Est. $250,000

Deadline to Apply:

Est. April 29th, 2026.

Objective:

Develop a whole blood product or substitute to aid in hemorrhage control for Military Working Dogs (MWD) after battlefield injury that can be used near the point of injury (POI) and throughout the continuum of care to reduce morbidity and mortality.

Description:

This topic is in support of the DoD Working Dog Strategic Research Plan concerning solutions for bleeding control and coagulopathy support.1 The Military Working Dog (MWD) provides a unique and important service to the warfighter. MWDs serve as sentries, perform tracking and patrol, and are used for the detection of explosives. These activities come with a high risk of injury. Uncontrolled hemorrhage following traumatic injury accounts for over 45% of all MWD battlefield deaths2. The current standard of care for hemorrhage in the MWD is to provide immediate fluid therapy through the delivery of crystalloid fluids as the first-line treatment, which is then followed by a synthetic colloid or hypertonic saline. These treatments also require the administration of supplemental oxygen to maintain appropriate oxygen levels and for the survival of the MWD3. To improve their survival rates, the development of a shelf stable canine whole blood product or substitute is a critical priority

The goal of this topic is to develop a stable canine whole blood product and/or substitute (i.e. hemoglobin or polymer oxygen carriers), intended for canine use at both POI and throughout the continuum of care. The product should have a shelf-life of greater than 3 years and be thermal stable (-9℃ to 60℃) to ensure accessibility in operational environments. The product must primarily replicate the oxygen carrier characteristics of whole blood and demonstrate the ability to be used safely and effectively to treat blood loss following traumatic injury. This research topic does not support the use of canines for testing purposes. Any animal testing would require use of suitable animal models that would approximate the response of a canine.

Blood products derived from canine donors must be negative for canine red blood cell antigens DEA 1.1 and DEA 1.2. Donor animals must also be tested for blood borne diseases including canine brucellosis, hemobartonellosis, Borrelia burgdorferi (Lyme disease), Dirofilaria immitis (heartworm disease), Ehrlichia canis, Rocky Mountain spotted fever, Coccidioides immitis, Babesia canis, Babesia gibsoni, Mycoplasma haemocanis and plasma levels of von Willebrand factor. All donor animals must be current on immunizations for canine distemper, hepatitis, parainfluenza, leptospirosis, parvovirus, Bordatella, coronavirus and rabies virus as applicable.

Who will win?

If you can achieve the objective above better than any other company on the market, you have a very high-likelihood of success and should apply.

Who is eligible to apply?

Any company that meets the following criteria:

• For-profit company

• U.S.-owned and controlled.

• 500 or fewer employees (including affiliates)

How Can BW&CO Help?

1) End-to-end support including, strategy, writing of the full proposal, and administrative & compliance support.

2) Proposal strategy and review.

3) Administrative & compliance support.

Request to talk with a member of our team by completing the form below:

Development of Small Molecules with Antifungal Properties for Safe Use in Human Patients (Direct to Phase II) - SBIR DHA26BZ01-DV005

Disclaimer:
This topic was temporarily posted by the Department of War SBIR Program on March 2nd 2026 and removed the following day.
We believe this topic is planned to be released once the SBIR program is reauthorized; however, this topic may ultimately be modified or withdrawn.

Sign up below to be notified as soon as this topic is released again. In the meantime, we’d recommend you start planning to respond if within your capabilities.

Funding Amount:

Est. $1.3 Million

Deadline to Apply:

Est. April 29th, 2026.

Objective:

This topic is intended for technology proven ready to move directly into Phase II and accepts Direct to Phase II proposals only. The proposed research will focus on identifying compounds with broad-spectrum activity against clinically relevant fungal pathogens while minimizing toxicity to humans. The primary objective is to identify a small molecule with fungicidal properties that are safe for human use, with FDA clearance.

Description:

Fungal infections represent a growing global health challenge, particularly among immuno-compromised individuals. Invasive fungal infections caused by pathogens such as Candida species, Aspergillus species, Fusarium species, and Mucor species are associated with high morbidity and mortality rates. Fungal infections are associated with 130k hospitalizations, 13 million outpatient visits, and result in a financial burden of $19 billion on the civilian health care sector. Fungal wound infections in particular are also growing challenge for the military. Despite the availability of antifungal agents, current treatments are often limited by toxicity, drug resistance, and narrow-spectrum activity. The emergence of multidrug-resistant fungal strains, such as Candida auris, has further exacerbated the need for novel antifungal therapies. Small molecules with antifungal properties offer a promising avenue for addressing these challenges. Their ability to target specific fungal pathways, combined with the potential for oral bioavailability and low manufacturing costs, makes them ideal candidates for therapeutic development. However, significant scientific and technical hurdles remain with the discovery and optimization of small molecules that are both effective against fungal pathogens and safe for human use. Qualified proposals should identify small molecules with antifungal properties from an existing library. These small molecules should be active against all of the following fungi: Fusarium species, Aspergillus species, Candida auris, or Mucorales species. Qualified molecules will have antifungal activity at nanomolar concentrations. Further, these small molecules must have a cytotoxicity profile similar, or better than Amphotericin B.

Who will win?

If you can achieve the objective above better than any other company on the market, you have a very high-likelihood of success and should apply.

Who is eligible to apply?

Any company that meets the following criteria:

• For-profit company

• U.S.-owned and controlled.

• 500 or fewer employees (including affiliates)

How Can BW&CO Help?

1) End-to-end support including, strategy, writing of the full proposal, and administrative & compliance support.

2) Proposal strategy and review.

3) Administrative & compliance support.

Request to talk with a member of our team by completing the form below:

Low-Cost, Phased Array Antennas for Collaborative Jamming in sUAS Swarms - SBIR Topic DAF26TZ01-NV004

Disclaimer:
This topic was temporarily posted by the Department of War SBIR Program on March 2nd 2026 and removed the following day.
We believe this topic is planned to be released once the SBIR program is reauthorized; however, this topic may ultimately be modified or withdrawn.

Sign up below to be notified as soon as this topic is released again. In the meantime, we’d recommend you start planning to respond if within your capabilities.

Funding Amount:

Est. $140,000

Deadline to Apply:

Est. April 29th, 2026.

Objective:

Develop a low-cost, phased array antenna system and associated signal processing techniques for collaborative jamming applications using small to medium-sized sUAS swarms (3-7 units).

Description:

This topic addresses the need for affordable and scalable jamming capabilities leveraging sUAS swarms. Instead of focusing on individual, high-power jammers, this STTR seeks to develop a collaborative jamming approach using multiple sUAS equipped with low-cost phased array antennas.

The key innovation is the development of a low-cost phased array antenna system that can be precisely controlled to focus jamming energy on specific targets. By coordinating the signals from multiple sUAS in a swarm, the effective jamming power can be significantly increased. The focus on low to medium-sized swarms (3-7 units) allows for manageable coordination and control strategies.

This approach offers several advantages over traditional jamming techniques, including:

 Increased jamming effectiveness through beamforming.

 Improved resilience through redundancy.

 Reduced risk of detection and counter-attack.

 Lower cost compared to high-power jamming systems.

Who will win?

If you can achieve the objective above better than any other company on the market, you have a very high-likelihood of success and should apply.

Who is eligible to apply?

Any company that meets the following criteria:

• For-profit company

• U.S.-owned and controlled.

• 500 or fewer employees (including affiliates)

How Can BW&CO Help?

1) End-to-end support including, strategy, writing of the full proposal, and administrative & compliance support.

2) Proposal strategy and review.

3) Administrative & compliance support.

Request to talk with a member of our team by completing the form below:

DIBC: Domestic Processing Capabilities of Critical Minerals

Below is a brief summary. Please check the full solicitation before applying (link in resources section).

Executive Summary:

The Defense Industrial Base Consortium (DIBC) has released RPP-CM-26-01: Domestic Processing Capabilities of Critical Minerals to strengthen U.S. defense supply chains.

The RPP closes: March 20, 2026, at 5:00 PM (ET). Late submissions may not be reviewed or considered.

This opportunity supports projects that establish, expand, or scale domestic processing capabilities for critical minerals essential to national defense. Awards will be issued through Other Transaction (OT) authority under 10 U.S.C. § 4021 (Research) or 10 U.S.C. § 4022 (Prototype).

If your company operates anywhere across the mineral value chain — from extraction to refining to recycling — and addresses at least one in-scope mineral, this is a high-priority DoD-backed industrial base investment opportunity.

How much funding would I receive?

The solicitation does not specify award amounts, minimum or maximum funding levels, number of awards, or total program funding.

Phase 2 submissions will include full pricing documentation. The Government will evaluate cost reasonableness and feasibility.

For projects:

• Over $100M but not $500M, additional cost feasibility standards apply.

• Over $500M, use of authority must be essential to meet critical national security objectives.

All agreements are generally expected to be fixed-price with milestone payments, although other award types may be proposed and negotiated.

What could I use the funding for?

Projects must address at least one of the following minerals:

• Arsenic

• Bismuth

• Gadolinium

• Germanium

• Graphite

• Hafnium

• Nickel

• Samarium

• Tungsten

• Vanadium

• Ytterbium

• Yttrium

• Zirconium

And must align with at least one of six Areas of Interest (AOIs):

AOI 1 – Raw Mineral Sourcing and Beneficiation

• Feasibility studies

• Infrastructure improvements

• Capital investments

• Productivity enhancements

• Expansion of mining capacity

AOI 2 – Separation and Processing

• Conversion to intermediate chemical forms (e.g., oxides, chlorides, salts)

AOI 3 – Metal Production, Metallization, Refining, and Upscaling

• Smelting

• Metal purification and refining

AOI 4 – Alloying and Finish Processing

• Alloy production

• Coating or plating

• Production of materials ready for integration into supply chains

AOI 5 – Recycling, Recovery, and Alternative Sourcing

• Recovery from mine tailings, scrap, industrial waste, end-of-life materials

AOI 6 – Supporting Supply Chains

• Production of chemical reagents, key inputs, tooling, production equipment

• Qualification of materials for DoD systems

Projects may span multiple stages of the value chain and may include co-products if at least one in-scope mineral is produced.

Are there any additional benefits I would receive?

This opportunity is structured under Other Transaction (OT) authority, which:

• Is not subject to the FAR

• Allows flexible commercial terms

• Enables milestone-based payment structures

• May support follow-on production without further competition under 10 U.S.C. § 4022(f), if the prototype is successfully completed

Submissions may also be placed in a 24-month “basket” for potential future award consideration.

The Government may also leverage additional financial tools such as:

• Direct equity stakes

• SAFE instruments

• Convertible notes

• Revenue share agreements

• Offtake agreements

• DPA Title III loans, loan guarantees, or purchase commitments

What is the timeline to apply and when would I receive funding?

RPP Release Date: February 27, 2026
RPP Closes: March 20, 2026, at 5:00 PM (ET)

The Government may close the RPP at any time. After closure, submissions will not be accepted.

The solicitation does not specify an award timeline or expected funding start date.

The review process includes:

Phase 1: Quad Chart submission

• Evaluated for relevance and feasibility

• Selected companies invited to Phase 2

Phase 2: Full proposal package

• Includes Project Execution Plan, pricing, certifications, Environmental Assessment Questionnaire

Only selected Phase 1 applicants will move to Phase 2.

Where does this funding come from?

This opportunity is issued by the Washington Headquarters Services, Acquisition Directorate (WHS/AD) under the Defense Industrial Base Consortium (DIBC).

It supports the mission of Industrial Base Policy (IBP) within the Office of the Under Secretary of War for Acquisition and Sustainment (OUSW(A&S)).

Funding is aligned with:

• Industrial Base Analysis and Sustainment (IBAS)

• Defense Production Act (DPA) Title III authorities

Who is eligible to apply?

Only Defense Industrial Base Consortium (DIBC) Consortium Members may submit.

Additional requirements:

• Must submit through ATI’s Business Information Data System (BIDS)

• Must be registered in SAM (System for Award Management)

• Must not be suspended or debarred

• Must meet responsibility determination standards

For Prototype authority under 10 U.S.C. § 4022, eligibility requires one of the following:

• Significant participation by a Nontraditional Defense Contractor (NDC) or Nonprofit Research Institution (NRI),

• Complete participation by a small business, or

• At least one-third resource contribution by a consortium member other than the above.

Foreign investment or control must be disclosed.

What companies and projects are likely to win?

The Government will evaluate proposals based on:

Phase 1:

• Relevance to the AOI

• Merit and feasibility

Phase 2:

• Relevance to the AOI

• Technical merit and feasibility

• Reasonableness of schedule

• Reasonableness and adequacy of cost

• Data rights assertions

Projects must clearly demonstrate:

• Impact on defense supply chains

• Production volumes

• Advancement in TRL and MRL

• Commercialization pathway

• Mitigation of global supply chain vulnerabilities

Holistic, integrated, scalable solutions across multiple value chain stages are encouraged.

Are there any restrictions I should know about?

Key restrictions include:

• Submissions must follow mandatory templates.

• Files must be unencrypted, under 5MB.

• No reimbursement for proposal costs.

• Classified material is not allowed.

• CUI submissions must comply with NIST SP 800-171r2.

• Supply chain reporting is required (including vendor data and part traceability).

• Mandatory Government terms apply under the DIBC Base Agreement.

• The Government retains broad discretion and may decline any proposal.

How long will it take me to prepare an application?

This is a two-phase process.

Phase 1:

• Quad Chart (mandatory template)

Phase 2 (by invitation only):

• Cover Page (2 pages)

• Project Execution Plan (15 pages)

• Affirmation of Business Status Certification

• Price proposal and justification

• Environmental Assessment Questionnaire

Preparation time will depend on project complexity. The solicitation does not specify an estimated preparation timeline.

How can BW&CO help?

BW&CO can:

• Determine alignment with IBAS vs. DPA Title III authorities

• Position your project across the mineral value chain

• Develop a compliant Quad Chart

• Build a defensible milestone-based pricing structure

• Align TRL/MRL progression to evaluation criteria

• Structure cost share or resource contribution documentation

• De-risk data rights assertions

• Prepare Phase 2 documentation under strict OT requirements

We ensure your submission aligns precisely with AOI criteria and evaluation factors.

How much would BW&CO Charge?

We have both fractional engagements ($250 an hour) and full engagements ($9,000) available.

Additional Resources

Review the solicitation here.

Air Force: AERIAL LAYER NETWORKING & TRANSMISSION TECHNOLOGIES

Below is a brief summary. Please check the full solicitation before applying (link in resources section).

Executive Summary:

The Air Force Research Laboratory (AFRL), Information Directorate (Rome Research Site), is soliciting white papers under BAA FA8750-23-S-7002 for advanced research in Aerial Layer Networking & Transmission Technologies.

This is an Open, 2-Step Broad Agency Announcement (BAA) focused on enabling self-forming, self-healing, resilient airborne networks that operate in contested and degraded environments.

White papers will be accepted until 0500 PM EST on 30 September 2027, and this BAA will close on 30 September 2027.

While submissions are accepted on a rolling basis, AFRL recommends aligning to fiscal year targets to maximize funding probability. If this topic aligns with your capabilities, early submission materially improves your chances of selection.

This is a multi-year, $99.5M opportunity with potential awards ranging from $1M to $10M — and up to $49.5M in certain cases.

How much funding would I receive?

• Total BAA funding: Approximately $99.5M

• Funding by fiscal year:

  • FY26 – $19.9M

  • FY27 – $19.9M

• Typical individual awards:

  • Normally range from $1M to $10M

  • Period of performance typically not to exceed 36 months

  • Potential exists for awards up to $49.5M

Multiple awards are anticipated. The Air Force reserves the right to award zero, one, or more awards depending on funding availability and proposal quality.

What could I use the funding for?

Funding supports research, development, integration, test, evaluation, and experimentation of technologies for Airborne Network Connectivity and Dissemination, including:

Airborne Network Management & Monitoring

• Self-managing and self-healing wireless networks

• Software Defined Networking (SDN)

• Network Function Virtualization (NFV)

• Monitoring and management of tactical data link (TDL) networks

Robust Airborne Networking

• Resilient networking in contested environments

• Mesh networking technologies

• RF front ends, radios, modems

• Security and reliability improvements

• Apertures and waveforms

Demonstrable Network Technologies

• Advanced radios and networking technologies

• Proof-of-concept demonstrations

• Lower-cost demonstrations leveraging AFRL infrastructure

AESA-Based Tracking Systems

• Analog active electronically steered array (AESA) technology

• Embedded control solutions for modular AESA panels

• Electronic tracking algorithms

• Small form-factor RF hardware

• Communications system integration and characterization

Both fundamental and non-fundamental research may be awarded. The Government retains sole discretion on instrument type and publication restrictions.

Are there any additional benefits I would receive?

Potential benefits include:

• Ability to receive FAR-based contracts, grants, cooperative agreements, or Other Transactions (OTs)

• For Other Transaction for Prototype (10 USC 4022) awards:

  • Potential transition to a follow-on production contract or transaction without further competition if the prototype is successfully completed

• Engagement and dialogue with AFRL prior to submission

• White paper feedback within 45 days of submission

What is the timeline to apply and when would I receive funding?

This is a rolling, open BAA.

White papers will be accepted until 0500 PM EST on 30 September 2027. The BAA will close on 30 September 2027.

Where does this funding come from?

Funding is provided by:

Department of the Air Force
Air Force Materiel Command
Air Force Research Laboratory (AFRL)
Information Directorate – Rome Research Site

Assistance Listing Number: 12.800

Statutory authorities may include:

• 10 USC 4021

• 10 USC 4022

• 10 USC 4023

Who is eligible to apply?

All qualified offerors who meet BAA requirements may apply.

What companies and projects are likely to win?

White papers and proposals are evaluated in descending order of importance based on:

1. Overall Scientific and Technical Merit

2. Related Experience relevant to USAF and Joint DoD missions

3. Openness, Maturity, and Assurance of Solution

4. Reasonableness and Realism of Costs

Projects that:

• Advance resilient airborne networking in contested environments

• Demonstrate operational transition potential

• Leverage existing standards and capabilities

• Present technically sound and executable plans

are aligned with stated priorities.

Are there any restrictions I should know about?

Key restrictions include:

• Foreign participation is prohibited except as explicitly permitted for fundamental research

• Classified work may require SECRET or TOP SECRET facility clearance

• Export control registration (DD Form 2345) may be required

• SBIR data rights are non-negotiable

• Non-SBIR data rights are subject to negotiation

• Cost sharing is not required and is not a selection factor

• Certified cost and pricing data required for contracts exceeding $2M ($7.5M for small businesses or nontraditional defense contractors)

• Human subject research requires IRB and AFRL-level approval

• Security Risk Review required for Senior/Key Personnel and Covered Individuals

• GAAP compliance required for OTs

• SPRS Basic NIST SP 800-171 DoD Assessment required

• AFRL supplemental OCI restrictions prohibit concurrent SETA/A&AS support and technical performance

Failure to follow white paper formatting instructions may result in rejection.

How long will it take me to prepare an application?

Step One requires a 3–5 page white paper including:

• Title, period of performance, estimated cost

• Task objective

• Technical summary and deliverables

Formatting must comply with BAA instructions (double-spaced, 12-point font minimum).

If invited to Step Two, a full technical and cost proposal will be required per the AFRL BAA Guide and RI-Specific Proposal Preparation Instructions (latest versions).

Preparation time will depend on complexity. The solicitation does not specify expected preparation duration.

How can BW&CO help?

BW&CO can:

• Assess strategic fit before submission

• Refine your white paper to align precisely with AFRL evaluation criteria

• Position technical merit and transition potential clearly

• Structure cost strategy for FAR-based or OT pathways

• Identify and mitigate OCI, FOCI, and S&T Protection risks

• Support full proposal development if invited to Step Two

We ensure your submission is compliant, competitive, and aligned to Air Force mission priorities.

How much would BW&CO Charge?

We have both fractional engagements ($250 an hour) and full engagements ($4,000) available.

Additional Resources

Review the solicitation here.

Air Force: AFRL/RX Functional Materials Open BAA

Below is a brief summary. Please check the full solicitation before applying (link in resources section).

Executive Summary:

The Air Force Research Laboratory (AFRL), Materials & Manufacturing Directorate, is seeking white papers under the AFRL/RX Functional Materials Open BAA (FA8650-22-S-5002). This is a two-step, rolling Broad Agency Announcement focused on innovative functional materials that enable new warfighting capabilities and improve size, weight, power (SWaP), reliability, maintainability, and lifecycle cost.

White Papers may be submitted at any time upon issuance of this BAA until 28 October 2026 3:00 PM Wright-Patterson AFB, OH Local time . Early submission is encouraged.

Total anticipated funding under this BAA is approximately $48,000,000. Multiple awards are anticipated, but the Air Force reserves the right to award zero, one, or more contracts.

If you are developing advanced photonic materials, nanoelectronic materials, quantum materials, soft matter, biomaterials, or related enabling technologies aligned with AFRL/RX core competencies, this is an open, flexible vehicle to secure non-dilutive federal R&D funding through 28 October 2026 3:00 PM Wright-Patterson AFB, OH Local time .

How much funding would I receive?

This BAA has total anticipated funding of approximately $48M across FY22–FY26 .

• FY26: ~$8.5M

The solicitation does not specify minimum or maximum award sizes per project.

The Air Force anticipates awarding multiple awards but reserves the right to award zero, one, or more contracts .

Each award is anticipated to be between 12 to 60 months for the technical effort plus an additional 3 months for reporting .

All funding is subject to availability and Government discretion .

What could I use the funding for?

Funding supports research aligned with the AFRL/RX Functional Materials mission, including:

Photonic Materials Core Competencies

• Optical materials and processes

• Hardened materials and processing

• Electro-Optic/Infrared (EO/IR) sensor protection

• Laser materials and structural protection

Nanoelectronic Materials Core Competencies

• Nanoscale transport materials and processes

• Ultra-wide bandgap semiconductors

• 2D materials

• Magnetoelectric and memristor materials

• Heterogeneous integration

Quantum Semiconductor Materials and Processes

• Quantum-enabled sensors and electronics

• Infrared sensing and hyperspectral imaging

• Secure communications and electronic warfare

• Quantum memory or transduction systems

Soft Matter and Biomaterials

• Stimuli-responsive polymers

• Flexible/stretchable electronics

• Wearable sensors

• Bioelectronics and biofunctionalization

• Biomanufacturing and biodegradation

• Synthetic biology for materials development

Work may include studies, research, experiments, characterization, processing, modeling, software, proof-of-concept development, and prototype hardware and software .

Deliverables may include data, software, prototypes, demonstration components/systems, and material samples, as required .

Are there any additional benefits I would receive?

Potential benefits include:

• Flexible award instruments: FAR-based contracts, Other Transactions (OT) for Prototype, OT for Research, grants, or cooperative agreements

• Anticipated use of Cost Plus Fixed Fee (CPFF) contracts

• Opportunity to transition technologies to future Government needs (explicitly evaluated in proposal review)

• Direct engagement and dialogue with AFRL prior to proposal submission

The Government will receive Unlimited Rights in noncommercial technical data and software developed exclusively with Government funds , which is important to consider in your IP strategy.

What is the timeline to apply and when would I receive funding?

This is a two-step process.

Step 1: White Paper
White Papers may be submitted at any time upon issuance of this BAA until 28 October 2026 3:00 PM Wright-Patterson AFB, OH Local time .

• Government review is anticipated to take 30 working days .

• Offerors will be notified whether they are recommended to submit a full proposal on or about 30 days after receipt .

Step 2: Full Proposal

• Only offerors who submitted a White Paper are eligible for award .

• Full proposals must be submitted within 30 working days of the proposal request .

Award timing is not specifically stated and depends on funding availability and successful negotiations.

The BAA remains open and effective until 28 October 2026 .

Where does this funding come from?

Funding comes from the Air Force Research Laboratory (AFRL), Materials and Manufacturing Directorate, Functional Materials Division (AFRL/RXA) .

Broad Agency Announcement Number: FA8650-22-S-5002
CFDA Number: 12.800 Air Force Defense Research Sciences Program .

Who is eligible to apply?

This is an unrestricted solicitation .

• Small businesses are encouraged to propose .

• There are no limits on the number of white papers/proposals an offeror may submit .

• Cost sharing is not required .

Foreign participation:

• AFRL is authorized to exclude all foreign participation at the prime contractor level .

• Foreign contractors are advised to notify the Contracting Officer before responding .

• Export control laws may apply, and a Certified DD Form 2345 may be required .

Government agencies must pursue participation outside this announcement .

What companies and projects are likely to win?

White Papers are evaluated (equal importance) on:

• Whether the technical approach is consistent with the technologies listed in the BAA

• Whether the research is of interest to the Government

• Whether appropriate funding is available

Full Proposals are evaluated primarily on Technical merit, including:

• Unique and innovative approach

• Advances in knowledge and state of the art

• Transition potential to future Government needs

• Understanding of scope

• Sound technical approach and risk mitigation

• Qualifications of personnel

• Availability of necessary facilities

Cost/Price is a substantial factor but ranked second to technical merit .

Projects that demonstrate innovation, transition potential, and alignment to AFRL functional material core competencies are most competitive.

Are there any restrictions I should know about?

Key restrictions include:

• Strict White Paper page limit: 4 pages plus 1 Quad Chart (5 total pages) .

• Strict Technical Proposal page limit: 20 pages plus 1 Quad Chart (21 total pages), plus separate 10-page SOW .

• Export control requirements (ITAR/EAR) may apply .

• Program security classification may be up to and including SECRET .

• Data rights: Government receives Unlimited Rights in noncommercial technical data and software developed exclusively with Government funds .

• GFP is not anticipated .

Late submissions due to installation security delays will be considered “late” .

How long will it take me to prepare an application?

White Paper (Step 1):

• 4 pages plus 1 Quad Chart

• Requires technical summary and Rough Order of Magnitude (ROM) cost estimate .

Full Proposal (Step 2):

• 20-page technical/management volume + 1 Quad Chart

• Separate 10-page Statement of Work

• Detailed cost/business proposal with full cost element breakdown .

The solicitation does not estimate preparation time. Preparation time will depend on complexity, internal cost systems, and whether certified cost or pricing data is required.

How can BW&CO help?

BW&CO can support you by:

• Aligning your technology to the correct AFRL/RX core competency

• Shaping your White Paper to pass peer/scientific review criteria

• Structuring your Quad Chart for clarity and impact

• Developing a compliant 20-page technical proposal and 10-page SOW

• Building a defensible cost model aligned with FAR and DFARS requirements

• Managing data rights assertions and export control positioning

We focus on positioning your innovation for Selectable categorization under AFRL’s technical-first review process.

How much would BW&CO Charge?

We have both fractional engagements ($250 an hour) and full engagements ($4,000) available.

Additional Resources

Review the solicitation here.

Navy: Autonomous Systems to Reduce Risk Warfighters Encounter

Below is a brief summary. Please check the full solicitation before applying (link in resources section).

Executive Summary:

The Department of the Navy, Naval Sea Systems Command (NAVSEA), Naval Surface Warfare Center (NSWC) Crane Division has released Special Notice N0016426SNB34 titled “Autonomous Systems to Reduce Risk Warfighters Encounter.”

This is a Request for Information (RFI) seeking input from industry on Uncrewed System (UxS) solutions (UGV, UAV, USV, UUV) that reduce risk to warfighters.

The Government may issue a future Request for Solutions (RFS) and award a Project Order under the Expeditionary Missions Consortium (EMC2) Other Transaction Agreement (OTA) in accordance with 10 U.S.C. § 4022.

The Response Date is Mar 30, 2026 2:00 PM EDT.
If you have a relevant UxS platform, you should evaluate this immediately.

How much funding would I receive?

Although the solicitation does not explicitly state a funding amount, contract opportunities typically follow within the range of $500k to $5m.

What could I use the funding for?

Funding is not specified at this stage.

However, the RFI is focused on autonomous Uncrewed System (UxS) solutions (UGV, UAV, USV, UUV) that reduce risk to warfighters and meet the following required criteria:

REQUIRED (must meet Questions 1–3):

• Total system weight: 45 lbs or less

• Battery life: Minimum 30-minute run time after deployment

• Minimum speed: Must keep pace with a human (between 2.5 and 4 mph)

The RFI also requests additional information on:

• Carrying capacity

• Safety features (redundant safety, deployment delay timers)

• Cost and production rate

• Blue UAS status

• TRL

• ATAK compatibility

• Autonomy capabilities

• Operation in contested environments

• Emission profile (auditory, visual, thermal)

• Kinetic/non-kinetic launcher integration

Are there any additional benefits I would receive?

The notice states:

• Responses may be shared with other partner organizations for additional use cases.

• Submission could potentially lead to contact from NSWC Crane personnel for further information.

• Participation positions you for potential future EMC2 RFS opportunities.

What is the timeline to apply and when would I receive funding?

• RFI Release Date: 10 February 2026

• Response Date: Mar 30, 2026 2:00 PM EDT

• Inactive Date: Apr 14, 2026

Where does this funding come from?

• Department of Defense

• Department of the Navy

• Naval Sea Systems Command (NAVSEA)

• Naval Surface Warfare Center (NSWC) Crane Division

• Issued under the Expeditionary Missions Consortium (EMC2)

• Potential awards under Other Transaction Agreement (OTA) authority in accordance with 10 U.S.C. § 4022

Who is eligible to apply?

The RFI is issued to the general public and industry.

All interested parties should visit https://emccrane.org/ to become a member of the consortium to view future possible RFS opportunities.

What companies and projects are likely to win?

While no evaluation criteria are provided, the RFI clearly prioritizes systems that:

• Weigh 45 lbs or less

• Provide at least 30 minutes of run time

• Move at 2.5–4 mph

• Demonstrate autonomy capabilities

• Potentially integrate with ATAK

• Can operate in contested environments

• Have known TRL levels

• Provide clear cost and production scalability

Are there any restrictions I should know about?

Key restrictions include:

• Submissions must be non-proprietary

• Do not submit classified information

• No marketing/advertising pictures

• No hyperlinks allowed

• File types limited to Microsoft Word, PDF, or PowerPoint

• File size must not exceed 10MB

• Page limits:

  • Word/PDF: Not to exceed 5 pages

  • PowerPoint: Not to exceed 5 slides

• Font: Times New Roman 10 (or larger)

• Must answer required questions in numbered format

• Must clearly indicate “N/A” where applicable

How long will it take me to prepare an application?

The submission is limited to:

• 5 pages (Word/PDF) or

• 5 slides (PowerPoint)

Formatting requirements are strict but concise.

For a company with an existing UxS platform that meets the REQUIRED criteria, preparation time is likely moderate. The exact time required is not specified in the notice.

How can BW&CO help?

BW&CO can:

• Assess whether your UxS meets the REQUIRED criteria

• Position your technology clearly against the numbered RFI questions

• Frame autonomy, TRL, ATAK, and contested-environment capabilities strategically

• Ensure compliance with formatting and non-proprietary requirements

• Prepare you for a potential future EMC2 Request for Solutions (RFS)

How much would BW&CO Charge?

We have both fractional engagements ($250 an hour) and full engagements ($13,000 + 5%) available.

Additional Resources

Review the solicitation here.

Vulcan: Position, Navigation, & Timing at the Tactical Edge

Below is a brief summary. Please check the full solicitation before applying (link in resources section).

Executive Summary:

Cyber & Specialist Operations Command is seeking Assured and Alternate Position, Navigation, & Timing (APNT) technologies to enable Force Elements to operate in GNSS denied, contested, or degraded environments.

This opportunity is structured as a Scout Card submission for Market Research purposes.

The submission deadline is 30 Apr 2026 : 17:59 GMT-6. The call opened on 22 Jan 2026 : 18:00 GMT-6. If your technology supports dismounted soldiers, vehicles, maritime mobility, or uncrewed systems in contested PNT environments, you should assess fit and prepare a submission before 30 Apr 2026 : 17:59 GMT-6.

How much funding would I receive?

Although the solicitation does not explicitly state a funding amount, contract opportunities typically follow within the range of $500k to $5m.

What could I use the funding for?

Funding use is not specified in the solicitation.

The description indicates interest in APNT technologies for:

• Dismounted Soldiers

• Maritime Mobility (Surface and Sub-Surface)

• Land Mobility Vehicles

• Uncrewed Vehicles (in all domains)

Technologies may be:

• Hardware based

• Software based (e.g., data fusion engines)

Technologies should be compatible with existing systems (plug and play).

Are there any additional benefits I would receive?

Additional benefits are not specified in the solicitation.

What is the timeline to apply and when would I receive funding?

Open Date: 22 Jan 2026 : 18:00 GMT-6
Deadline: 30 Apr 2026 : 17:59 GMT-6

The deadline to submit a Scout Card is 30 Apr 2026 : 17:59 GMT-6.

Where does this funding come from?

The opportunity is issued by Cyber & Specialist Operations Command.

Who is eligible to apply?

The posting does not state whether applicants must be small businesses, non-traditional contractors, primes, academic institutions, or other entities.

What companies and projects are likely to win?

The solicitation indicates interest in technologies that:

• Enable operation in GNSS denied, contested, or degraded environments

• Support dismounted soldiers or vehicle platforms (static and on-the-move)

• Are compatible with existing systems (plug and play)

• Can be hardware-based or software-based (including data fusion engines)

Are there any restrictions I should know about?

Restrictions, cost share requirements, intellectual property terms, and compliance requirements are not specified in the solicitation.

How long will it take me to prepare an application?

Preparation time will depend on the amount of technical detail required in the Scout Card. Specific page limits or format instructions are not specified.

How can BW&CO help?

BW&CO can:

• Assess alignment of your APNT technology with the stated use cases

• Refine positioning for GNSS denied, contested, or degraded environments

• Translate technical capabilities into mission-aligned language

• Prepare and structure your Scout Card submission

We focus on clearly articulating operational value, system compatibility, and deployment readiness.

How much would BW&CO Charge?

We have both fractional engagements ($250 an hour) and full engagements ($13,000 + 5%) available.

Additional Resources

Review the solicitation here.

CDMRP: FY26 Lung Cancer Research Program (LCRP)

Below is a brief summary. Please check the full solicitation before applying (link in resources section).

Executive Summary:

Act now to prepare for the FY26 Lung Cancer Research Program (LCRP) funding opportunities — anticipated to open on Grants.gov imminently. This chance is critical for investigators aiming to drive innovative, high-impact research that will eradicate deaths and suffering from lung cancer, with a focus on outcomes that benefit Service Members, Veterans, their families, and the general public. Exact pre-application and application deadlines will be posted in the final NOFOs on Grants.gov when released.

Pre-Applications are due on 6/23/26 and 8/18/26.

Full Applications are due on 9/02/26.

How much funding would I receive?

Award amounts for the FY26 LCRP are specified by mechanism:

• Idea Development Award: Up to $800,000 total costs over 3 years.

• Translational Research Award (Level 1): Up to $1.35M total costs over 3 years.

• Translational Research Award (Level 2 – Clinical Trial Option): Up to $1.85M total costs over 4 years.

• Patient-Centered Outcomes and Survivorship Award: Up to $975,000 total costs over 3 years.

What could I use the funding for?

Funding supports research in the following Areas of Emphasis:

• Biology & Etiology: Mechanisms of lung cancer initiation and progression.

• Prevention & Risk Reduction: Innovative prevention and recurrence reduction strategies.

• Detection, Diagnosis & Surveillance: Improved early detection and disease monitoring.

• Treatment & Prognosis: Novel treatments, biomarkers, and metastasis management.

• Health Outcomes & Survivorship: Survivorship quality of life, comorbidity impacts, and disparities reduction.

Each mechanism has specific focus and eligibility criteria detailed in the forthcoming NOFOs.

Are there any additional benefits I would receive?

The pre-announcement does not specify additional benefits (e.g., data resources or training support). These may be described in the final funding opportunity announcements.

What is the timeline to apply and when would I receive funding?

• Pre-Applications are due on 6/23/26 and 8/18/26.

• Full Applications are due on 9/02/26.

Where does this funding come from?

Funding arises from the FY26 Defense Appropriations Act and is administered through the Congressionally Directed Medical Research Programs (CDMRP) within the Defense Health Agency Research and Development.

Who is eligible to apply?

Eligibility (e.g., investigator types, institution requirements) will be outlined in the final NOFOs. The pre-announcement does not include full eligibility details.

What companies and projects are likely to win?

Applicants are more competitive if they:

• Align tightly with one or more Areas of Emphasis.

• Demonstrate innovation and potential clinical impact.

• Address relevance to military health (e.g., Veteran populations, exposures).

Are there any restrictions I should know about?

• Some mechanisms (e.g., Idea Development) do not allow clinical trials.

• Specific restrictions and requirements will be in the NOFOs once released.

How long will it take me to prepare an application?

Preparation time depends on the mechanism, project maturity, and whether preliminary data or partnerships are needed. Start planning now to align with the mechanisms and Areas of Emphasis.

How can BW&CO help?

BW&CO can help you:

• Decode the final NOFO requirements.

• Align your research strategy to maximize impact.

• Draft and polish pre-applications/ applications.

• Manage submission logistics and compliance.

How much would BW&CO Charge?

We have both fractional engagements ($250 an hour) and full engagements ($13,000 + 5%) available.

Additional Resources

Review the solicitation here.

USASOC CY2026 C-sUAS Open Call

Below is a brief summary. Please check the full solicitation before applying (link in resources section).

Executive Summary:

U.S. Army Special Operations Command (USASOC) is seeking counter-small Unmanned Aircraft Systems (C-sUAS) technologies to protect Army Special Operations Forces (ARSOF) operating in austere, high-risk environments.

Small UAS pose a growing threat through ISR, targeting, and direct attack capabilities. USASOC is looking for TRL 4–7 solutions that improve detection and defeat capabilities while minimizing the electromagnetic signature of the user.

The submission deadline is 01 Dec 2026 : 22:59 GMT-6.

Submissions are currently open and will be accepted beginning 02 Feb 2026 : 23:00 GMT-6 through 01 Dec 2026 : 22:59 GMT-6. If this is aligned with your technology, you should plan to submit before the deadline.

How much funding would I receive?

Typical funding is around $500k - $2m.

What could I use the funding for?

This opportunity supports engagement objectives including:

• Capability Demonstration

• Market Research

• Tech Experimentation

USASOC is specifically interested in C-sUAS technologies that are:

• TRL 4–7

• Handheld or body worn sensors for sUAS detection

• Handheld RF detect and defeat solutions

• GNSS denial or spoofing technologies

• Expeditionary Fixed Sites (EFS) that are man packable <50lbs

• EFS that provide detection capabilities of group 1–3 UAS

All technologies should minimize the electromagnetic signature of the user.

Are there any additional benefits I would receive?

Additional benefits are not specified in the solicitation.

What is the timeline to apply and when would I receive funding?

Open Date: 02 Feb 2026 : 23:00 GMT-6
Deadline: 01 Dec 2026 : 22:59 GMT-6

The deadline to submit is 01 Dec 2026 : 22:59 GMT-6.

Where does this funding come from?

The opportunity is issued by U.S. Army Special Operations Command (USASOC).

Who is eligible to apply?

Eligibility requirements are not specified in the provided solicitation materials.

Entity type restrictions (e.g., small businesses, large businesses, academic institutions, non-profits) are not specified.

What companies and projects are likely to win?

Based on the stated interests, USASOC is seeking technologies that:

• Address sUAS threats to ARSOF

• Fall within TRL 4–7

• Provide handheld, body-worn, RF detect/defeat, GNSS denial/spoofing, or man-packable (<50lbs) Expeditionary Fixed Site capabilities

• Detect group 1–3 UAS

• Minimize the electromagnetic signature of the user

Are there any restrictions I should know about?

Submission requires:

• Uploading a quad chart of your technology (See template)

How long will it take me to prepare an application?

The only required submission material specified is a quad chart of your technology.

Preparation time will depend on how quickly you can complete the required quad chart.

How can BW&CO help?

BW&CO can:

• Assess whether your technology aligns with the stated TRL 4–7 and C-sUAS requirements

• Refine your positioning to clearly address ARSOF operational needs

• Develop and optimize your quad chart to align with USASOC’s stated interests

• Ensure your submission directly reflects the language and priorities in the solicitation

How much would BW&CO Charge?

We have both fractional engagements ($250 an hour) and full engagements ($4,000) available.

Additional Resources

Review the solicitation here.

Offensive Subsea and Seabed Warfare (SSW) Exercise Barb 26

Below is a brief summary. Please check the full solicitation before applying (link in resources section).

Executive Summary:

COMSUBFOR is seeking emerging technologies to support Offensive Subsea and Seabed Warfare (SSW) operations in alignment with U.S. national security and DoD strategic guidance. The focus is on maintaining undersea dominance by modernizing warfighting capabilities through persistent innovation and integration of emerging technologies.

This effort supports broader Joint Force and AUKUS Pillar 2 requirements. Technologies must directly enhance U.S. Submarine Force and AUKUS mission effectiveness and lethality in a contested undersea environment.

The application deadline is March 22nd. If you are developing autonomous, robotic, or remotely operated systems capable of conducting Offensive Seabed Attack missions, you should begin preparing immediately.

How much funding would I receive?

Typical funding is around $500k - $2m.

What could I use the funding for?

Funding would support technologies that enhance the execution of Offensive Subsea and Seabed Warfare (SSW) operations.

Area of Interest (AOI-1): Offensive Seabed Attack

Submissions should address:

• Deploying and operating robotic autonomous systems

• Deploying and operating remotely operated systems

• Targeting adversary seabed systems

• Achieving kinetic and non-kinetic effects

• Covering the entire kill chain from deployment through battle damage assessment

Technologies must be directly relevant to enhancing mission effectiveness and lethality in a contested undersea environment.

Are there any additional benefits I would receive?

This effort supports U.S. Submarine Force priorities and AUKUS Pillar 2 requirements.

Additional benefits beyond potential integration to enhance U.S. Submarine Force and AUKUS mission effectiveness are not specified.

What is the timeline to apply and when would I receive funding?

The application deadline is March 22nd.

Where does this funding come from?

This effort is issued by COMSUBFOR in accordance with U.S. national security and DoD strategic guidance.

Who is eligible to apply?

Eligibility requirements are not specified in the provided solicitation materials.

Entity type restrictions (e.g., small businesses, large businesses, academic institutions, non-profits) are not specified.

What companies and projects are likely to win?

Projects that:

• Enhance Offensive Subsea and Seabed Warfare (SSW) capabilities

• Improve mission effectiveness and lethality in contested undersea environments

• Support U.S. Submarine Force and AUKUS Pillar 2 requirements

• Address the full kill chain from deployment to battle damage assessment

Are there any restrictions I should know about?

• Cost share requirements are not specified.

• Technology readiness level (TRL) requirements are not specified.

• Export control, security clearance, or classification requirements are not specified.

• Other restrictions are not specified in the provided materials.

How long will it take me to prepare an application?

Given the March 22nd deadline, companies should assume an accelerated preparation timeline.

How can BW&CO help?

BW&CO can:

• Translate your seabed or autonomous systems technology into a mission-aligned narrative tailored to COMSUBFOR priorities

• Map your solution to the Offensive Seabed Attack AOI and clearly articulate full kill chain impact

• Position your company to demonstrate relevance to U.S. Submarine Force and AUKUS Pillar 2 mission effectiveness

• Develop concise, defense-aligned technical and capability briefs

How much would BW&CO Charge?

We have both fractional engagements ($250 an hour) and full engagements ($4,000) available.

Additional Resources

Review the solicitation here.

U.S. Army FUZE: xTech|Adaptive Strike Competition

Below is a brief summary. Please check the full solicitation before applying (link in resources section).

Executive Summary:

The U.S. Army FUZE xTech Program has launched the xTech|Adaptive Strike competition, seeking ready-to-deploy, affordable technologies that address urgent battlefield capability gaps in reconnaissance, drones, power generation, and counter-UAS.

The Army intends to award up to $1.5 million in total cash prizes and may pursue follow-on contracts or agreements with finalists or winners.

Registration information and submission upload must be received by 5:00 PM ET on March 13, 2026. Submissions received after the deadline will not be considered.

If you have a commercially available or near-commercial solution that can be fielded rapidly and demonstrated in live Soldier exercises, this is a time-sensitive opportunity to engage directly with Army end-users.

How much funding would I receive?

The total prize pool is $1.5 million under 10 U.S.C. §4025 (Prize Competitions).

Awards are structured as follows:

Part 1 – Concept White Paper

• Up to 20 semifinalists

• $25,000 each

Part 2 – Semifinals Soldier Exercise

• Up to 10 finalists

• Additional $50,000 each

Part 3 – Finals Soldier Exercise

• Up to five (5) winners

• Additional $100,000 each

Total potential per winner (if selected through all phases):

• $25,000 + $50,000 + $100,000 = $175,000

In addition to prize money, winners may have an opportunity to submit for a follow-on contract or agreement, subject to availability of funds and technical needs.

What could I use the funding for?

Prize funds are awarded as part of a competitive down-select mechanism and are not described as cost-reimbursable project funding.

The competition is designed to:

• Stimulate innovation

• Identify promising technologies for national security applications

• Enable rapid technology maturation

• Accelerate transition to operational forces

Participants must demonstrate solutions in one of four capability areas:

1. Extended On-Station Time and Range for Medium/Long-Range Reconnaissance (MRR/LRR)

   • Complete system cost must be less than $350,000

   • Must provide 10 testable units for the June 2026 Semi-Finals if selected

2. Affordable Drones and Loitering Munitions for Scaled Operations

   • Must provide 10 testable units for the June 2026 Semi-Finals if selected

3. Power Generation for Ground Units with sUAS

   • Must provide 10 testable units for the June 2026 Semi-Finals if selected

4. Counter-Unmanned Aerial Systems (c-UAS) for Soldier Operations

   • Must provide 6 testable units for the June 2026 Semi-Finals if selected

Are there any additional benefits I would receive?

Participants may receive:

• Direct engagement with U.S. Army and Department of War (DoW) subject matter experts

• Live Soldier exercise participation

• Evaluator feedback during each part of the competition

• Exposure to Army end-users and operational units

• Potential follow-on opportunities using various statutory authorities, including:

  • 10 U.S.C. § 4114

  • 10 U.S.C. § 4022

  • 10 U.S.C. § 4023

  • 10 U.S.C. § 4001

  • 10 U.S.C. § 4021 (OTA)

  • 10 U.S.C. § 3458

  • 15 U.S.C. § 3703

  • 15 U.S.C. § 638 (SBIR/STTR)

Finalists may be contacted separately for additional proposal opportunities outside the prize competition.

What is the timeline to apply and when would I receive funding?

Registration information and submission upload must be received by 5:00 PM ET on March 13, 2026. Submissions received after the deadline will not be considered.

Proposed schedule (subject to change):

• February 23 – March 13, 2026 – Part 1: Concept white paper & video submission period

• April 17, 2026 – Semifinalists announced

• June 1–19, 2026 – Part 2: Semifinals Soldier Exercise (NTC, Fort Irwin, CA)

• July 2026 – Finalists announced

• October 29 – November 28, 2026 – Part 3: Finals Soldier Exercise (NTC, Fort Irwin, CA)

• November 2026 – Winners announced

Prize payments are tied to advancement through each phase.

Dates and times are subject to change.

Where does this funding come from?

The competition is conducted under 10 U.S.C. § 4025, which authorizes the use of prize competitions to stimulate innovation and identify promising technologies for national security applications.

The initiative is led by:

• The U.S. Assistant Secretary of the Army for Acquisition, Logistics and Technology (ASA(ALT))

• Joint Innovation Outpost (JIOP)

• U.S. Army 3rd Infantry Division (3ID)

• MARNE Innovation Center

Who is eligible to apply?

Eligible entities include:

• U.S.-based nonprofit organizations

• U.S.-based for-profit organizations (large and small businesses)

Each eligible entity:

• Shall be incorporated in, and maintain, a primary place of business in the U.S.

• Shall not be a U.S. Federal government entity or employ a U.S. Federal Employee acting within the scope of their employment

• Shall not be currently under contract, agreement or otherwise providing similar capabilities to the Government for work described in the problem statement

• Must have or be able to obtain a CAGE code if selected to advance

• Shall be at the sole discretion of the Government

Only one (1) submission per capability area per eligible entity is permitted.
If submitting to more than one (1) capability area, the technology solutions must be different.

What companies and projects are likely to win?

The Army is seeking commercially available or near-commercial technologies that:

• Address urgent operational capability gaps

• Are affordable and scalable

• Can be delivered within 180 days of challenge completion

• Can be demonstrated in live Soldier exercise events

• Meet unit quantity requirements for the June 2026 Semi-Finals

Submissions are evaluated using the following criteria and weights:

• Introduction – 7%

• Army Benefits – 30%

• Technical Approach – 20%

• System Scalability / Economics – 30%

• Commercial Potential – 10%

• Submission Quality – 3%

Proposals must include:

• A five (5)-page concept white paper using the required template

• A pre-recorded video of up to 10 minutes

• Evidence of ability to deliver specified test units for the June exercise

Submissions exceeding page or video limits will not be evaluated.

Are there any restrictions I should know about?

• Participants must assume risks and waive claims against the Federal Government, except in cases of willful misconduct.

• Additional documentation is required prior to exercise events to meet safety protocols.

• Failure to meet documentation deadlines or performance standards may result in disqualification.

• Full participation in the entire duration of the exercise event is required.

• Submissions are treated as privileged information and disclosed only for evaluation and program support.

Intellectual Property:

• The Federal Government may not gain an interest in IP developed by a participant without written consent.

• The Government may negotiate a license for the use of IP developed during the competition.

• Existing Government IP rights remain unchanged.

How long will it take me to prepare an application?

The application requires:

• A five (5)-page concept white paper using the required template

• A pre-recorded video (up to 10 minutes)

• Registration submission through the xTech portal

• Self-certification of minimum requirements

The solicitation does not specify an estimated preparation time.

How can BW&CO help?

BW&CO can:

• Determine which capability area best aligns with your technology

• Position your solution against the published evaluation criteria

• Develop a compliant five-page white paper using the required template

• Structure your narrative around Army Benefits, Scalability, and Technical Approach scoring weights

• Support video content strategy to align with evaluation expectations

• Prepare you for Soldier exercise engagement and potential follow-on pathways

We focus on translating commercial capability into Army-relevant value that scores.

How much would BW&CO Charge?

We have both fractional engagements ($250 an hour) and full engagements ($4,000) available.

Additional Resources

Review the solicitation here.

CDMRP: FY26 Orthopaedic Research Program (ORP)

Below is a brief summary. Please check the full solicitation before applying (link in resources section).

Executive Summary:

The FY26 Orthopaedic Research Program (ORP) pre-announcement outlines anticipated funding opportunities supporting innovative, high-impact research to advance treatment and rehabilitation for orthopaedic injuries sustained during combat and service-related activities. This pre-announcement is intended to help teams plan now; it is not a promise of funding. Full Funding Opportunity Announcements (FOAs) with submission deadlines will be posted on Grants.gov and eBRAP when released.

Pre-Application (Preproposal): August 19th

Application: November 18th

How much funding would I receive?

Specific award budgets and totals are not yet provided in the pre-announcement. A sampling of anticipated mechanisms includes:

• Applied Research Award – up to $950,000 total costs over up to 3 years.

• Clinical Research Award (Level 1) – up to $2,000,000 total costs (4-year max).

• Clinical Research Award (Level 2) – up to $3,200,000 total costs (4-year max).
  (Total awards by mechanism and number of awards are not specified at this stage.)

What could I use the funding for?

Projects must address one or more of the FY26 ORP focus areas, including:

• Battlefield fracture-related infection (prevention, early detection, eradication strategies).

• Composite tissue regeneration following high-energy extremity trauma.

• Ligamentous trauma treatments for musculoskeletal soft-tissue instability.

• Limb stabilization and wound protectants enabling prolonged care.

• Osseointegration outcomes for prosthetic limb interfaces.

• Return-to-duty strategies to optimize reintegration and reduce reinjury.

• Military women’s health impacts of orthopaedic care.
  Funding applies to research that improves patient function, restores mobility, and maximizes return to duty in military and service-related contexts.

Are there any additional benefits I would receive?

The pre-announcement does not list additional benefits (e.g., mentoring, training, networking) beyond funding support.

What is the timeline to apply and when would I receive funding?

• Pre-announcement release:February 24, 2026.

• FOAs release: Posted later on Grants.gov and eBRAP (dates not yet specified).

• Pre-Application (Preproposal): August 19th

• Application: November 18th

• Funding start dates: Determined after FOA release and award negotiations (not specified).
  (All deadlines and schedules will be in the final FOAs — not provided in this pre-announcement.)

Where does this funding come from?

Funding is authorized by the FY26 Defense Appropriations Act and administered by the Defense Health Agency Research and Development / Medical Research and Development Command (MRDC) through the Congressionally Directed Medical Research Programs (CDMRP).

Who is eligible to apply?

Eligibility for each award mechanism will be defined in the full FOAs. From the pre-announcement:

• Independent investigators at all career levels are eligible for many mechanisms, particularly clinical research awards.

• Preproposal required: Some mechanisms require a preproposal through eBRAP, and full application is by invitation only.
  (Complete eligibility details — including institution types, citizenship, and cost share — will be in the FOAs and are not specified here.)

What companies and projects are likely to win?

Specific companies or project profiles most likely to win are not described in the pre-announcement. Competitive applications will align with the ORP focus areas and demonstrate potential to advance orthopaedic care in military and clinical contexts.

Are there any restrictions I should know about?

• The ORP will not consider applications proposing strategies infeasible in battlefield environments for fracture-related infection or tissue regeneration alone.

• The program will not consider biomarker-only research.

• Preproposal submission is required for certain mechanisms; full applications may be by invitation only.

• All submissions must comply with final FOA instructions posted on Grants.gov.

How long will it take me to prepare an application?

With deadlines and FOA details not yet posted, exact preparation time cannot be stated. Given CDMRP’s typical structure, planning should begin now to develop compelling science narratives, compliance documents, and required eBRAP preproposals.

How can BW&CO help?

BW&CO can help you:

• Monitor FOA release dates and mechanism details.

• Translate the final FOA into a targeted application roadmap.

• Develop high-impact narrative, budget, and compliance materials.

• Guide submission strategy on eBRAP and Grants.gov.

• Support preproposal and full application review to maximize competitiveness.

How much would BW&CO Charge?

We have both fractional engagements ($250 an hour) and full engagements ($13,000 + 5%) available.

Additional Resources

Review the solicitation here.

Academic-Industrial Partnerships for Translation of Technologies for Diagnosis and Treatment (R01 - Clinical Trial Not Allowed)

Below is a brief summary. Please check the full solicitation before applying (link in resources section).

Executive Summary:

This NIH funding opportunity (PAR-25-338) opens a repeated standard R01 grant mechanism to support academic-industrial partnerships that translate scientific discoveries and engineering developments into new technologies, methods, tools, assays, devices, or systems relevant to disease diagnosis, risk assessment, detection, prevention, treatment, or monitoring — with the expectation of translation to use and end users. This NOFO does not allow clinical trials and does not support basic research that lacks a translational component. Multiple standard NIH due dates run through January 8, 2028 (expiration), with recurring application windows (e.g., Feb 5, 2026; Jun 5, 2026; Oct 5, 2026, etc.) — all due by 5:00 PM local time on each date.

How much funding would I receive?

Award budget limit: up to $499,000 per year in direct costs.

1. Maximum project period: 5 years.

2. Number of awards: contingent on NIH appropriations and meritorious applications (not specified).

What could I use the funding for?

Funds may be used to enhance, adapt, optimize, validate, and otherwise translate technologies, methods, assays, devices, or systems that:

• Address problems in biology, pathology, risk-assessment, detection, diagnosis, treatment, or monitoring disease.

• Advance capabilities that are suitable for end users in pre-clinical or clinical research or clinical care.

• Examples include diagnostic/imaging systems, informatics tools, analytical methods, harmonized data methods, shared research resources, and technologies optimized for low-resource settings.

Are there any additional benefits I would receive?

The NOFO does not include special supplements, set-aside support, or technical assistance beyond standard NIH funding. (Not specified in the NOFO.)

What is the timeline to apply and when would I receive funding?

• Open/earliest submission: January 5, 2025.

• Standard NIH due dates: recurring submission windows including Feb 5, Jun 5, Oct 5 of each calendar year, through January 8, 2028 (expiration). All are due by 5:00 PM local time.

• Applicants should allow time to correct any errors before each deadline.

• Estimated award start dates follow NIH standard review cycles (months after each review).

Where does this funding come from?

• Funding agency: National Institutes of Health (NIH), U.S. Department of Health and Human Services.

• Participating NIH components:

  • National Cancer Institute (NCI)

  • National Eye Institute (NEI)

  • National Institute of Dental and Craniofacial Research (NIDCR)

  • Office of Research on Women’s Health (co-funding support)

Who is eligible to apply?

Eligible applicant organizations include:

• Higher education institutions (public/private).

• Nonprofits (with or without 501(c)(3)).

• For-profit organizations (including small businesses).

• Local/state governments; federally recognized tribal governments.

• Federal agencies; non-U.S. entities (foreign) and foreign components of U.S. organizations.

Eligible individuals: Anyone with the skills/resources to carry out the proposed research as PD/PI.

What companies and projects are likely to win?

Likely competitive projects will:

• Form true academic-industrial partnerships with complementary expertise.

• Target translation of a technology/method toward a defined end-user application.

• Demonstrate a coherent plan to enhance, optimize, validate, or translate the proposed technology.

• Show clear metrics, milestones, and feasibility for implementation or adoption.

• Address problems relevant to participating NIH institutes.

Are there any restrictions I should know about?

• Clinical Trials: Not allowed under this NOFO.

• Commercial production: NOT supported; the grant supports translation up to pre-commercial readiness, not manufacturing.

• Basic research: Projects lacking translation emphasis are non-responsive.

• Applications must conform to NIH research and submission policies (e.g., DMS, registrations).

How long will it take me to prepare an application?

Time depends on readiness of data, partnerships, and NIH registrations (e.g., SAM, eRA Commons). Typical R01 applications require weeks to months of preparation, including:

• Strategic alliance planning

• Preliminary data assembly

• Detailed research strategy

• Budget and justification

• Registrations (SAM/eRA Commons) prior to submission (can take ~6+ weeks).

How can BW&CO help?

BW&CO can:

• Clarify partner roles and narrative strategy for academic-industrial teams.

• Translate technical aims into NIH-aligned specific aims and research strategy.

• Advise on regulatory, translational, and commercialization framing.

• Support budget planning consistent with NIH guidelines.

How much would BW&CO Charge?

We have both fractional engagements ($250 an hour) and full engagements ($13,000 + 5%) available.

Additional Resources

Review the solicitation here.

U.S. Army Futures Command (AFC) Broad Agency Announcement (BAA) - W519TC-25-S-0001

Below is a brief summary. Please check the full solicitation before applying (link in resources section).

Executive Summary:

The U.S. Army Futures Command (AFC), Artificial Intelligence Integration Center (AI2C) has released Broad Agency Announcement W519TC-25-S-0001 for Basic, Applied, and Advanced Scientific Research in artificial intelligence.

This is a continuously open five-year announcement valid throughout the period beginning 01 May 2024 – 31 May 2029, with proposals accepted through 11:59 PM Eastern Daylight Time on 31 MAY 2029.

AI2C is actively seeking white papers and proposals that advance Army-relevant AI technologies across autonomy, AI/ML, decision support, human-AI integration, distributed AI, and related foundational research areas.

Because this BAA is continuously open, companies can submit at any time before 11:59 PM Eastern Daylight Time on 31 MAY 2029, but new start awards are normally obligated early within each fiscal year . Early submission within the fiscal year cycle may improve timing alignment with available funds.

How much funding would I receive?

The solicitation does not specify a minimum or maximum award amount , but most awards range from $500k - $5m

Awards may be made using a variety of instruments, including:

• Procurement contracts

• Grants

• Cooperative agreements

• Technology Investment Agreements (TIAs)

• Other Transactions (OTs)

There is no stated funding cap, award ceiling, or target award size in the BAA.

New start awards are normally obligated early within each fiscal year.

What could I use the funding for?

Funding supports Basic Research, Applied Research, and Advanced Research in AI-related areas.

The BAA defines:

• Basic Research: Systematic study directed toward greater knowledge of fundamental aspects of phenomena without specific application in mind.

• Applied Research: Systematic expansion and application of knowledge to develop useful materials, devices, systems, or methods aligned to recognized Army needs.

• Advanced Research: Development of subsystems and components integrated into prototypes for field experiments or simulated environments, generally at Technology Readiness Levels 4, 5, or 6.

Foundational Research Topics of Interest include:

• Autonomous Platforms

• Artificial Intelligence and Machine Learning Algorithms (AI/ML)

• AI/ML Decision Support

• Human-AI Integration

• Synthetic Environments

• Distributed AI

• Underpinning Methodologies

• Special Topics (posted separately as amendments on SAM.gov)

There are no funding restrictions associated with this BAA.

Are there any additional benefits I would receive?

Depending on the instrument type, benefits may include:

• Potential use of Other Transactions (OTs), which may allow negotiation of expanded intellectual property protections.

• Technology Investment Agreements (TIAs) tailored for commercial firms or research involving commercial application.

• Opportunity for cost sharing, in-kind labor, or facility sharing (optional unless required by instrument type).

• Potential transition into acquisition pathways if research demonstrates military utility.

The BAA also envisions collaboration agreements where no funds are exchanged, such as Cooperative Research and Development Agreements (CRADAs).

What is the timeline to apply and when would I receive funding?

This BAA is a continuously open five-year announcement valid throughout the period beginning 01 May 2024 – 31 May 2029.

Proposals will be accepted through 11:59 PM Eastern Daylight Time on 31 MAY 2029.

New start awards are normally obligated early within each fiscal year.

There is no guaranteed award timeline specified. Award start dates are determined at the time of selection and award notice.

Applicants are encouraged, but not required, to submit a White Paper (limited to three pages) prior to submitting a full proposal.

Where does this funding come from?

Funding is issued by:

• U.S. Army Futures Command (AFC), Artificial Intelligence Integration Center (AI2C)

• Issuing Acquisition Office: U.S. Army Contracting Command – Rock Island Division

The CFDA Number and Title is:

• 12.630 – Basic, Applied, and Advanced Research in Science and Engineering

Awards are issued under statutory authorities including 10 U.S.C. 4001, 10 U.S.C. 4021, and 10 U.S.C. 4022.

Who is eligible to apply?

Eligible applicants include:

• Institutions of higher education

• Non-profit organizations

• For-profit organizations

• Domestic or foreign entities

However:

• Government laboratories

• Federally Funded Research and Development Centers (FFRDCs)

• U.S. Service Academies

are not eligible to participate as prime contractors or recipients .

Foreign organizations and foreign public entities may face security restrictions. Countries on the U.S. State Department List of Countries that Support Terrorism are excluded .

Generally, cost sharing is not required and is not an evaluation factor, except where required by certain instrument types such as OTs or TIAs.

What companies and projects are likely to win?

Proposals are evaluated on:

1. Scientific and Technical Merit (most important factor)

2. Potential Contribution to the Army mission

3. Qualifications and Capabilities of the team and institution

4. Cost (realism, affordability, appropriateness)

5. Past performance

All evaluation factors other than cost, when combined, are significantly more important than cost.

Projects that:

• Demonstrate clear Army relevance

• Advance state-of-the-art AI capabilities

• Show feasibility and potential transition value

• Align directly with identified foundational research topics

are most aligned with stated evaluation criteria.

Are there any restrictions I should know about?

Key restrictions and requirements include:

• No classified submissions .

• Registration in SAM is required prior to award .

• Unique Entity Identifier (UEI/DUNS) required .

• Human Subjects and Animal Use protections apply where relevant .

• Export control (ITAR) compliance may apply to contracts .

• Grants and cooperative agreements are subject to Army Research Risk Assessment Program (ARRP) review for foreign influence risk .

• Proposals must comply with strict formatting limits (e.g., 23-page technical limit) .

Failure to meet submission requirements may result in rejection.

How long will it take me to prepare an application?

The BAA includes a three-stage process:

1. Obtain UEI and register in SAM.

2. Optional White Paper (maximum three pages).

3. Full proposal submission (technical volume + cost volume) .

The technical portion (Abstract, Background, Application Potential, Technical Approach) is limited to 23 pages.

The BAA does not estimate preparation time. Preparation time will depend on:

• Whether you submit a white paper first

• Whether cost documentation (e.g., DCAA-accepted accounting system) is already in place

• Whether you pursue a contract, grant, cooperative agreement, TIA, or OT

For new DoD performers, preparation can be documentation-intensive.

How can BW&CO help?

BW&CO can support:

• Topic alignment to AI2C foundational research areas

• White paper drafting (3-page compliant format)

• Full technical volume development (23-page limit compliance)

• Cost volume structuring aligned with FAR/DFARS requirements

• OT and TIA strategy positioning

• Army relevance framing and transition strategy

• Risk mitigation narrative development

We ensure strict compliance with BAA formatting, eligibility, and evaluation criteria while positioning your technology for maximum Army relevance.

How much would BW&CO Charge?

We have both fractional engagements ($250 an hour) and full engagements ($15,000 + 5%) available.

Additional Resources

Review the solicitation here.

Biomedical Advanced Research and Development Authority (BARDA) Broad Agency Announcement (BAA)

Below is a brief summary. Please check the full solicitation before applying (link in resources section).

Executive Summary:

The BARDA Broad Agency Announcement (BAA-23-100-SOL-00004, Amendment 7) is a continuously open funding vehicle supporting advanced R&D of medical countermeasures (MCMs) for CBRN threats, pandemic influenza, and emerging infectious diseases. This is one of the most flexible and recurring federal funding pathways for biotech, diagnostics, and platform companies.

The submission deadline is September 25, 2028, at 4:30pm Eastern Time, unless otherwise indicated in an AOI.

This is not a traditional one-time grant—BARDA accepts submissions on a rolling basis and invites full proposals after an initial screening. Companies with relevant technologies should engage early to maximize alignment and feedback.

How much funding would I receive?

• Not specifically stated, but most awards range between $500k - $5m.

• BARDA states:

  • “Multiple awards of various values are anticipated”

  • Funding depends on:

    • Program priorities

    • Technical merit

    • Fit to Areas of Interest (AOIs)

    • Available funds

What could I use the funding for?

AOI #1: CBRN Vaccines

• 1.1. [SUSPENDED] Needle-Free Technologies to Administer Licensed Vaccines

• 1.2. Sudan Virus and Marburg Virus

  • Advanced development of monovalent vaccines against Sudan virus and Marburg virus

  • Candidate must have:

    • Demonstrated protection from lethal challenge in non-human primate studies

    • Phase 1 clinical safety data

  • Goal includes completion of Phase 2 clinical study(ies) and manufacture of sufficient clinical trial material to support outbreak response

• 1.3. Flexible Vaccine Manufacturing Platform Technologies

  • Antigen production technologies that can:

    • Progress from gene sequence to IND submission in <6 months

    • Be successfully applied to multiple infectious disease targets

    • Scale to >1 million doses

  • Proposals should address at least two CBRN threats, with optional work for additional threats

AOI #2: CBRN Antivirals and Antitoxins

• 2.1. [SUSPENDED] Anthrax Antitoxins

• 2.2. Botulism Antitoxins

  • Next-generation MCMs against botulinum neurotoxins

  • Priority for products with efficacy against serotypes A-G

  • Includes antibody-based products, small molecules, or syndrome-based therapeutics

• 2.3. Smallpox Antivirals

  • Next-generation antiviral therapeutics against smallpox

  • Preference for products with a different class or mechanism than existing FDA-approved smallpox therapeutics

  • Combination therapy potential is preferred

• 2.4. Filovirus Antivirals

  • Therapeutics for Ebolavirus and Marburgvirus

  • Includes:

    • Broad-spectrum antivirals

    • Monoclonal antibodies and related products

    • Syndrome-based therapeutics

    • Post-exposure prophylaxis products

AOI #3: Antimicrobials

• 3.1. MDR Bacteria and Biothreat Pathogens

  • Drug candidates active against biothreat pathogens and/or drug-resistant secondary infections during a CBRN, pandemic influenza, or emerging infectious disease incident

• 3.2. MDR Fungal Infections

  • Broad-spectrum antifungal candidates with novel mechanisms of action

  • Includes Candida species, including Candida auris, drug-resistant Aspergillus species, and rare molds

AOI #4: Radiological/Nuclear Threat Medical Countermeasures

• 4.1. Acute Radiation Syndrome (ARS)

  • Therapeutics for:

    • Thrombocytopenia

    • Pancytopenia

    • Endothelial and vascular injury

    • GI or lung injury

    • Delayed effects of acute radiation exposure

    • Cellular therapies and hematopoietic stem/progenitor cell technologies

• 4.2. Uncontrolled Hemorrhage

  • Blood products and related technologies

  • Therapeutics that replace blood products or extend the resuscitation window

  • Therapies for cellular metabolism and hemostasis dysfunction

• 4.3. Radiation Injury and Trauma Pathophysiologies

  • Biomarker assays

  • Imaging and diagnostic tools

  • Therapeutic solutions targeting injury pathophysiology

• 4.4. Enabling Technologies and Platforms

  • Tissue chips and microphysiological systems

  • Platforms for easier therapeutic use in resource-limited settings

  • Potency assays for cellular therapies and next-generation blood products

• 4.5. [SUSPENDED] Decorporation Agents

AOI #5: Chemical Medical Countermeasures

• 5.1. Pulmonary Agents

  • MCMs to prevent and treat lung damage from agents such as chlorine and phosgene

  • Includes ARDS, pulmonary edema, pulmonary endothelial vascular injury, chemical pneumonitis, reactive airway syndrome, and pulmonary fibrosis

• 5.2. Pharmaceutical-based Agents, including Opioids and Other Respiratory Depressants

  • MCMs for life-threatening overdose from PBAs, respiratory depressants, and/or multi-drug toxicity

  • Threat-agnostic respiratory stimulants are of particular interest

  • Candidates not involving opioid receptor antagonism are prioritized

• 5.3. Vesicants

  • MCMs to ameliorate harmful effects of sulfur mustard and lewisite

  • Preference for drugs that prevent or ameliorate chronic effects

• 5.4. Nerve Agents and Organophosphorus (OP) Pesticides

  • Repurposing or label expansion of already FDA-approved medications

  • Includes treatment of muscarinic, nicotinic, seizure-causing effects, and benzodiazepine-refractory seizures

• 5.5. Knockdown Agents/Cellular Asphyxiants

  • MCMs for cyanides, hydrogen sulfide, phosphine, and related threats

  • Preference for treatments also safe and effective against smoke inhalation-related cyanide exposure

• 5.6. Novel MCM Delivery Mechanisms

  • Improved methods and/or routes of administration for new and existing MCMs

• 5.7. Innovative Approaches to Understanding Chemical Injury in Humans

  • In vitro humanized systems, organoids, organ chips, microphysiological systems, and human-relevant animal models

  • Goal is to identify therapeutic targets and support new treatment development

Under AOI #5, BARDA states that all aspects of advanced clinical stage drug development are permissible for funding, including:

• Nonclinical studies

• Safety

• Toxicology

• PK/PD

• Manufacturing

• Analytical assay development and validation

• Clinical studies, including pediatric studies

• Regulatory submission preparation

• Post-approval requirements

AOI #6: Burn and Blast Medical Countermeasures

• 6.1. Burn and Blast Traumatic Injuries Management

  • Products for full-thickness burns, severe lacerations, penetrating trauma, crush injuries, nerve and vascular trauma

  • Includes enabling technologies such as devices, software, AI-assisted capabilities, pain management, and clinical guidelines

• 6.2. Management of Head Injuries in Trauma

  • Non-invasive or minimally invasive technologies to detect neurotrauma

  • Triage tools for acute traumatic brain injuries

  • Special interest in technologies detecting/localizing internal brain hemorrhage and elevated intracranial pressure/edema

• 6.3. Hemorrhage Control

  • Gels, devices, and other adoptable MCMs for severe hemorrhage from lacerations and junctional wounds

  • Also includes technologies for early detection/localization of internal hemorrhage

• 6.4. [SUSPENDED] Non-Autologous Topical Products to Prevent or Reduce Burn Wound Conversion

• 6.5. Management of Thoracoabdominal Trauma Injuries

  • Detection/diagnosis of internal injuries

  • Portable point-of-care ultrasound and similar technologies

  • Tools to improve management, monitoring, prognosis, and treatment decisions for blunt trauma

• 6.6. Musculoskeletal Injuries

  • Technologies to evaluate, diagnose, triage, and manage traumatic MSK injuries

  • Includes complex fractures, soft tissue injuries, tendons, ligaments, and AI-enabled imaging improvements

• 6.7. [SUSPENDED] Special Instruction for Health Economic Impact Assessment of Burn MCMs

• 6.8. Platform Agnostic Software for AI Augmentation of Ultrasound Imaging Data

  • Software connecting ultrasound devices with minimal API development

  • AI/ML support for EMS and ED triage

  • Product should seek FDA clearance as required

AOI #7: Diagnostics

BARDA divides diagnostics into four threat areas:

• 7.1. Biothreats

• 7.2. Antibiotic resistance

• 7.3. Pandemic influenza

• 7.4. Threat-agnostic diagnostics

Subpoints:

7.1. Biothreat Agent Diagnostics

• 7.1.1. Biothreat Agent Diagnostics: Point-of-Care

  • Rapid point-of-care diagnostic systems for listed biothreats

  • TRL 4 or greater required

• 7.1.2. Biothreat Agent Diagnostics: Laboratory

  • Automated laboratory assays for listed biothreats

  • Single-threat and multiplex assays will be considered

  • TRL 4 or greater required

• 7.1.3. Biothreat Agent Diagnostics: Filovirus Point-of-Care and Remote Settings

  • Rapid, accurate, CLIA-waivable, field-useable molecular diagnostics for filoviruses

  • Must at minimum detect Ebola virus, Sudan virus, Bundibugyo virus, Taï Forest virus, and Marburg virus

  • TRL 3 or greater, with expectation of advancing to TRL 4 and regulatory submission

7.2. Antibiotic Resistance Diagnostics for Priority Bacterial Pathogens

• 7.2.1. Bacterial Antimicrobial Resistance (AMR) Testing Direct from Specimen

  • Rapid ID and AMR testing from primary clinical specimens

  • Broad pathogen coverage

  • TRL 4 or greater required

• 7.2.2. [SUSPENDED] Bacterial vs. Viral Infections: Point-of-Care

• 7.2.3. AMR Sequencing Solutions

  • Sample-to-answer sequencing solutions for identifying pathogens with known and/or novel resistance determinants

  • TRL 4 or greater required

7.3. Influenza Diagnostics

• 7.3.1. Influenza Testing in an OTC and CLIA-waived environment

  • Molecular or high-sensitivity antigen tests for influenza A and B

  • Point-of-care and home-use

  • TRL 4 or greater required

• 7.3.2. [SUSPENDED] Pan-Influenza Diagnostics: Point-of-Care or Laboratory

• 7.3.3. [SUSPENDED] Point-of-Care Multiplex Assay for Detection of Influenza Virus

7.4. Threat-Agnostic Diagnostics

• 7.4.1. Metagenomic Next-Generation Sequencing (mNGS)-Based Diagnostic for Viral and Bacterial Pathogens

  • Advanced development, clinical evaluation, and FDA clearance of mNGS-based assays

  • Laboratory and point-of-care tests are sought

  • TRL 4 or greater required

AOI #8: IEID Vaccines

• 8.1. Advanced Development of Faster or More Effective Vaccines

  • 8.1.1. Faster Vaccines

    • Licensed, domestically manufactured vaccines with goals of:

      • 100 days from sequence availability to release of first doses

      • 130 days from sequence availability to doses sufficient to immunize the U.S. and global population

  • 8.1.2. More Effective Vaccines

    • Products or formulations such as adjuvants or other technologies that:

      • Elicit a priming and protective response in immunologically naïve recipients with a single dose

      • Improve stability, sustainability, and/or utility of stockpiled vaccines

  • 8.1.3. Clinical trials to expand the age range on the label of currently licensed vaccines

• 8.2. Innovative Vaccine Product and Production Enhancements

  • 8.2.1. Platform technologies

  • 8.2.2. Manufacturing

  • 8.2.3. Assays for product release

  • 8.2.4. Administration

AOI #9: IEID Therapeutics

• 9.1. Broad Spectrum Antiviral Therapeutics for Influenza

  • New broad-spectrum direct- or indirect-acting antivirals for respiratory viral infections including influenza in outpatient settings

• 9.2. Immune Modulators or Therapeutics Promoting Lung Repair

  • Therapeutics to prevent, treat, and/or improve outcomes of ARDS caused by pandemic or seasonal influenza and other respiratory infections

• 9.3. Pre-exposure Prophylaxis – Influenza

  • Antivirals for pandemic preparedness and for people with inadequate influenza vaccine response

  • Preference for long-acting products providing at least one month of protection from a single dose

• 9.4. [SUSPENDED] COVID-19 Monoclonal Antibody Therapeutics for Treatment

AOI #10: ImmuneChip+

BARDA seeks advanced microphysiological systems and tissue-chip technologies.

Offerors should address two or more of these five components:

• 1) Infection with a relevant pathogen, insult with toxins/toxicants, exposure to acute ionizing radiation, or exposure to chemical agents

• 2) Integration of at least two different tissues in addition to immune component(s)

• 3) Near-continuous monitoring of the MPS for at least two weeks

• 4) Semi-automated or automated manufacturing of the device

• 5) Biological characterization of the MPS and recapitulation of existing clinical data in response to injury/morbidity and various MCMs

BARDA also explicitly encourages proposals in these topic areas:

• Development of modular multi-tissue systems

• Characterization studies on known approved and unapproved therapeutic candidates

• Natural history studies of acute radiation syndrome in target organ systems

• Natural history studies in animal chip models

• Vascularized models with endothelial cells that can model vascular injury

AOI #11: [SUSPENDED] COVID-19 Immune Assay(s) Development and Implementation

AOI #12: Flexible and Strategic Therapeutics (FASTx)

BARDA seeks adaptable antiviral platforms.

Required elements in Market Research Abstract and Proposal submissions:

• Preliminary platform data demonstrating in vitro efficacy of a candidate against filoviruses

• Proposal to develop and advance candidates against two unique targets:

  • 1 filovirus

  • 1 “to be determined” HHS priority threat

• Identification of technical gaps/challenges, such as:

  • Formulation

  • Manufacturability

  • Safety and toxicity

  • Delivery to target tissues

  • Pharmacokinetics

  • Efficacy

• Justification of how common aspects of the platform can accelerate regulatory review of later products

Additional guidance:

• Therapeutic indications are preferred

• Post-exposure prophylaxis will only be considered for filovirus targets

• For this AOI, BARDA states that potential offerors must request a pre-submission call before submitting an MRA

• MRAs must be received by April 24, 2026 for consideration of an award in the 2026 fiscal year

Are there any additional benefits I would receive?

Yes. BARDA provides non-dilutive capital plus strategic support, including:

• Access to:

  • Animal study networks

  • Flexible manufacturing facilities

  • Regulatory and clinical expertise

• Potential progression through:

  • FDA approval, licensure, or clearance

• Engagement with:

  • BARDA experts

  • Interagency partners (PHEMCE)

What is the timeline to apply and when would I receive funding?

Submission deadline:

• September 25, 2028, at 4:30pm Eastern Time, unless otherwise indicated in an AOI.

Process (3 stages):

1. Stage 1 – Pre-submission call (optional)

   • Can occur anytime

   • Response within ~1 week

2. Stage 2 – Quad Chart + Market Research Abstract

   • Submit anytime before September 25, 2028, at 4:30pm Eastern Time, unless otherwise indicated in an AOI

   • BARDA response: within 120 days

3. Stage 3 – Full Proposal (by invitation or direct submission)

   • Deadline: September 25, 2028, at 4:30pm Eastern Time, unless otherwise indicated in an AOI

   • Response: within 120 days

Where does this funding come from?

• U.S. Department of Health and Human Services (HHS)

• Administration for Strategic Preparedness and Response (ASPR)

• Biomedical Advanced Research and Development Authority (BARDA)

Authorized under:

• Federal Acquisition Regulation (FAR)

• Pandemic and All-Hazards Preparedness legislation

Who is eligible to apply?

• Open to ALL responsible sources, including:

  • Private companies

  • Startups

  • Academic institutions

  • Government labs

  • Teams/consortia

Requirements:

• Must be registered in SAM.gov

Special cases:

• FFRDCs and government entities must justify eligibility

Encouraged participants:

• Small businesses

• Women-, minority-, veteran-owned firms

• HBCUs and other underserved institutions

What companies and projects are likely to win?

BARDA prioritizes:

Strong alignment with AOIs, including:

• Vaccines, therapeutics, diagnostics, and platforms for:

  • CBRN threats

  • Pandemic influenza

  • Emerging infectious diseases

High-performing proposals typically have:

• Advanced development stage (clear TRL justification)

• Strong technical and clinical data

• Clear FDA regulatory pathway

• Scalable manufacturing plan

• Commercial viability and sustainability

Evaluation criteria (in order):

1. Program relevance

2. Scientific and technical merit

3. Team capabilities and experience

Are there any restrictions I should know about?

Key restrictions include:

• No gain-of-function research

• All submissions must be unclassified

• Must comply with:

  • FDA regulations (GCP, GMP, GLP)

  • Export control laws

• Proposals must follow strict formatting and submission rules

• Costs to prepare proposals are not reimbursable

How long will it take me to prepare an application?

• Stage 2 (Quad Chart + Abstract):

  • Relatively lightweight (≤14 pages total)

• Stage 3 (Full Proposal):

  • Highly detailed and complex (up to ~120+ pages)

  • Includes:

    • Technical proposal

    • Cost proposal

    • Regulatory, manufacturing, and clinical plans

Estimated effort:

• Not specified in the solicitation

How can BW&CO help?

BW&CO can support you across all three BARDA stages:

• AOI targeting and fit assessment

• Stage 1 strategy and positioning

• Quad Chart + Market Research Abstract development

• Full proposal writing (technical + cost volumes)

• Regulatory and commercialization narrative alignment

• Review and red-teaming for BARDA evaluation criteria

How much would BW&CO Charge?

We have both fractional engagements ($250 an hour) and full engagements ($13,000 + 5%) available.

Additional Resources

Review the solicitation here.

Mojave Falcon 27: Technology Assessment Event

Below is a brief summary. Please check the full solicitation before applying (link in resources section).

Executive Summary:

The U.S. Army’s S-FCD is conducting current assessments on sustainment and logistics technologies during Mojave Falcon 27, taking place 14–27 August 2027 at Ft Hunter-Liggett, Camp Roberts, and Ft Irwin, California.

If you are building technology that advances Army Sustainment operations in contested, dispersed, and geographically isolated Large-Scale Combat Operations (LSCO) environments, this is a live assessment opportunity.

The submission deadline is 20 Mar 2026 : 22:59 GMT-6. Late submissions will not be accepted.

This is not a traditional grant with stated funding amounts. It is an opportunity to have your technology assessed during a major Army event. If your solution aligns with sustainment priorities, you should consider applying before 20 Mar 2026 : 22:59 GMT-6.

How much funding would I receive?

Although the solicitation does not explicitly state a funding amount, contract opportunities typically follow within the range of $500k to $5m.

What could I use the funding for?

Follow on contract awards can be used to optimize technology for a defense mission need and begin an engagement with the Army for further development or use.

Are there any additional benefits I would receive?

If selected, your technology would be assessed during Mojave Falcon 27 (14–27 August 2027).

The event will be conducted between:

• Ft Hunter-Liggett, CA

• Camp Roberts, CA

• Ft Irwin, CA

This provides:

• Direct exposure to Army sustainment stakeholders

• Operational assessment in LSCO-relevant environments

• Evaluation in contested, dispersed, and geographically isolated scenarios

What is the timeline to apply and when would I receive funding?

Open Date: 20 Feb 2026 : 10:00 GMT-6
Deadline: 20 Mar 2026 : 22:59 GMT-6

The assessment event (Mojave Falcon 27) will take place approximately 14–27 August 2027.

The solicitation does not specify:

• Selection notification dates

• Contract award dates

• Funding disbursement timing

The application deadline remains 20 Mar 2026 : 22:59 GMT-6.

Where does this funding come from?

The notice references S-FCD and the U.S. Army.

Who is eligible to apply?

Eligible applicants include:

• Traditional defense contractors

• Non-traditional defense contractors (as defined in 10 U.S.C. 2302(9))

• Foreign-owned businesses (independently or via teaming with U.S.-owned businesses)

Requirements:

• Registration in SAM.gov

• Registration in WAWF for invoicing

• Ability to meet export control requirements (if applicable)

What companies and projects are likely to win?

The Army requires integrating current functional technology to advance Army Sustainment operations that:

• Create significant advantages across the force

• Operate in contested environments

• Function in dispersed and geographically isolated LSCO environments

• Extend operational reach of units

• Prolong endurance during operations

• Enable freedom of action using new technology

Technologies aligned to these sustainment objectives are most consistent with the stated priorities.

Are there any restrictions I should know about?

If your technology is chosen for participation, you will be required to provide:

• Pictures of the technology

Drawings or electronic renderings will not be accepted in place of photographs.

How long will it take me to prepare an application?

The solicitation does not specify application length, required attachments (beyond the photo requirement if selected), or submission complexity.

Based on the limited information provided, preparation time is not specified in the solicitation.

How can BW&CO help?

BW&CO can:

• Assess whether your sustainment or logistics technology aligns with LSCO operational priorities

• Translate your technical capability into Army-relevant language

• Position your solution around operational reach, endurance, and freedom of action

• Prepare a concise, compliant submission aligned to the stated assessment criteria

How much would BW&CO Charge?

We have both fractional engagements ($250 an hour) and full engagements ($13,000 + 5%) available.

Additional Resources

Review the solicitation here.

H92240-26-S-C001 Naval Special Warfare Command Commercial Solutions Opening (CSO)

Below is a brief summary. Please check the full solicitation before applying (link in resources section).

Executive Summary:

Naval Special Warfare Command (NSWC) has released Commercial Solutions Opening (CSO) H92240-26-S-C001 to rapidly acquire innovative unmanned systems (UxS) capabilities for Special Operations Forces (SOF).

NSWC intends to award FAR-based Firm-Fixed-Price contracts and/or Other Transaction (OT) Agreements under 10 U.S.C. §§ 4021–23 to support:

• “UxS as a Service” subscription-based solutions

• First Person View (FPV) ISR operations

• FPV Kinetic operations

This is a multi-phase competitive process running throughout 2026/2027.

Deadlines:

• AOI 1 submissions are due 25 January 2026.

• AOI 2 and AOI 3 submissions are due 9 January 2026, 9 April 2026, 9 July 2026, and 9 October 2026.

If you have a deployable UxS platform, FPV ISR capability, or FPV kinetic solution with strong production readiness and compliance posture, this is an active acquisition pathway—not just research funding. Early submission increases the likelihood of engagement and Phase II selection.

How much funding would I receive?

The solicitation does not specify award amounts, funding ceilings, number of awards, or total program value.

Awards may be made as:

• FAR Part 12 Firm-Fixed-Price contracts

• Other Transaction (OT) Agreements under 10 U.S.C. 4022–23

Multiple awards may be made if solutions meet technical criteria and funds are available.

If an OT Prototype Project is awarded, there is potential for a noncompetitive follow-on production agreement under 10 U.S.C. 4022(f), subject to successful prototype completion.

What could I use the funding for?

Funding is intended to deliver operational unmanned system capabilities to NSWC and SOF operators.

AOI 1: “UxS as a Service”

Subscription-based models providing:

• Complete UxS systems

• Platforms and payloads

• Communications and data transfer equipment

• Software, AI, PED systems

• Command and Control (C2) software and AI

• Launch/recovery systems

• Attachments and modular components

• Updates, upgrades, training, maintenance, and spare parts

Offerors must clearly define:

• Number of systems available

• Delivery speed and replenishment rate

• Interoperability with C2 systems

• Modular Open Systems Approach compliance

• Regulatory and compliance posture

AOI 2: FPV ISR Operations

Solutions that improve individual operator situational awareness using FPV systems capable of:

• Locating, identifying, and reporting targets

• Multi-mission ISR configurations

• Advanced ease-of-use and operational capability

AOI 3: FPV Kinetic Operations

FPV systems that enable operators to kinetically engage targets, including:

• Configurable ISR/kinetic capability

• Payload flexibility

• Advanced control modes

Technical characteristics of interest include:

• 0m–50K operational distance

• 45–60 minute duration

• Autonomous capability

• Swarm and saturation capability

• GNSS resilience

• EMI resilience

• Maritime launch capability

• Waterproof ISR sUAS sub-surface launch

• Modular payload integration

• Ability to supply at least three (3) prototypes (if applicable)

The period of performance should generally be no greater than 12 months unless otherwise negotiated.

Are there any additional benefits I would receive?

This CSO offers:

• Direct access to NSWC and USSOCOM experimentation venues

• Potential collaborative Statement of Work development

• Eligibility for OT prototype awards

• Potential follow-on noncompetitive production agreements

• Possible external Venture Capital interest from strategic Government partners

Solutions are treated as commercial items under DFARS 212.70.

What is the timeline to apply and when would I receive funding?

Phase I – Solution Brief (White Paper / Scout Card)

Submit via Vulcan.

Deadlines:

• AOI 1: 25 January 2026

• AOI 2 & AOI 3: 9 January 2026, 9 April 2026, 9 July 2026, 9 October 2026

Government aims to provide:

• Phase I evaluation response within 45 days after submission

• Phase II evaluation notification within 30 calendar days of the demonstration/experimentation

Phase II – Demonstration / Pitch

• Conducted at NSWC or USSOCOM venues

• At offeror’s expense

• Must provide ROM pricing and schedule

• May require at least three (3) operational units and two (2) trained operators

Phase III – Proposal

• Invitation-only

• Collaborative SOW development

• Contract/OT negotiation

The solicitation does not specify award issuance timing beyond these evaluation targets.

Where does this funding come from?

Funding comes from:

• Naval Special Warfare Command (NSWC)

• United States Special Operations Command (USSOCOM)

• Department of War (DoW) (as referenced in the solicitation)

Awards are made under:

• FAR Part 12

• 10 U.S.C. §§ 4021–23 (Other Transaction Authority)

Who is eligible to apply?

Eligible applicants include:

• Traditional defense contractors

• Non-traditional defense contractors (as defined in 10 U.S.C. 2302(9))

• Foreign-owned businesses (independently or via teaming with U.S.-owned businesses)

Requirements:

• Registration in SAM.gov

• Registration in WAWF for invoicing

• Ability to meet export control requirements (if applicable)

• All Phase I submissions must be unclassified

Note: Some Phase II discussions may require personnel clearances depending on venue.

What companies and projects are likely to win?

Solutions will be evaluated individually based on:

Technical

• Merit and feasibility

• Relevance to AOI

• Ability to address vulnerabilities

• Innovation (as defined under DFARS 212.7001)

Importance to Agency Programs

• Operational relevance

• Business viability

• Commercial viability

Affordability

• Price and budgetary considerations

Strong candidates will demonstrate:

• Production readiness

• Supply chain transparency

• Compliance with NDAA and regulatory requirements

• Modular, interoperable architectures

• Clear operational utility to SOF

The Government reserves the right to move directly to award without demonstration.

Are there any restrictions I should know about?

• Phase II participation is at the offeror’s expense.

• Costs of preparing submissions are not reimbursed.

• Technical data may require export approvals.

• Compliance may include:

  • NDAA compliance

  • Remote ID

  • FAA/ICAO/DoW compliance

  • Cybersecurity

  • Insurance/liability

• Submissions must not exceed five (5) pages for Phase I Solution Brief (12-point font).

• Only a warranted Contracting or Agreements Officer can obligate the Government.

How long will it take me to prepare an application?

Phase I submission requirements:

• Maximum five (5) pages

• 12-point font

• Concise, substantive response

• Technical and business overview

• Capability differentiators

• Readiness timeline

• Rough Order of Magnitude schedule and budget

For companies with a mature UxS product and clear business model, preparation time is typically measured in weeks rather than months.

How can BW&CO help?

BW&CO can:

• Position your UxS or FPV capability against the correct AOI

• Refine your five-page Solution Brief to align with NSWC evaluation criteria

• Strengthen innovation framing under DFARS 212.7001

• Develop ROM pricing strategy

• Prepare you for Phase II demonstration requirements

• Support OT negotiation strategy and Phase III proposal development

This is an operational acquisition pathway. Positioning and clarity matter.

How much would BW&CO Charge?

We have both fractional engagements ($250 an hour) and full engagements ($13,000 + 5%) available.

Additional Resources

Review the solicitation here.

OUSW-R&E/P&E Joint Rapid Fielding Activity

Below is a brief summary. Please check the full solicitation before applying (link in resources section).

Executive Summary:

One Nation Innovation, in coordination with the Joint Rapid Fielding Activity (JRFA), is seeking qualified vendors to deliver prototype organizational, technical, and operational support services to accelerate emerging warfighting capabilities from prototyping through fielding to the Joint Force .

This opportunity focuses on building a scalable program management and technical support framework that enables rapid prototyping, experimentation, assessment, and transition of technologies aligned with Department of War (DoW) modernization and rapid capability development priorities .

The solicitation does not specify an application deadline.

If your firm can operate in classified environments, manage complex technical integrations, and accelerate technology transition at speed, this is a strategically positioned prototype opportunity with potential follow-on production or scaling awards.

How much funding would I receive?

It states that:

• This prototype will be awarded leveraging the One Nation Innovation Other Transactional Agreement (OTA) vehicle .

• The initial award may be augmented with additional prototype or production awards pending successful evaluation, operational fit, and government need .

• Multiple awards may be made based on technical merit, readiness, and mission alignment .

A Rough Order of Magnitude (ROM) cost estimate is required as part of the proposal .

What could I use the funding for?

Funding supports delivery of integrated organizational, technical, and operational support services to JRFA .

Activities may include:

• Disciplined program management and mission-engineering–informed planning

• Technology identification, maturation planning, and documentation

• Development of feasibility refinements, requirements clarification, and risk identification artifacts

• Preparation of technologies for operationally relevant testing, including safety, RMF, spectrum, airworthiness, logistics, and operator-facing materials

• Support for prototyping and experimentation events (planning, synchronization, data collection, troubleshooting, coordination)

• Integration risk identification and interoperability gap resolution

• Knowledge management systems, templates, taxonomies, and digital collaboration environments

• Outreach support to grow and nurture the defense industrial and innovation ecosystem

• Support for innovation burden sharing and experimentation with allies and security partners

Expected deliverables include:

• Monthly status reports

• Planning, maturation, and evaluation artifacts

• Readiness and integration materials

• Knowledge-management tools and repeatable processes

• Final report with metrics, lessons learned, and transition recommendations

• Other deliverables as required by the JRFA mission owner

Are there any additional benefits I would receive?

The solicitation states:

• The initial award may be augmented with additional prototype or production awards pending successful evaluation, operational fit, and government need .

• Successful solutions and prototypes may transition to follow-on task orders or scaling activities .

This creates a potential pathway beyond the initial prototype effort.

What is the timeline to apply and when would I receive funding?

This is an Open Challenge.

• Submissions remain open for extended durations.

• Submissions are generally reviewed biweekly.

• There is no specified application deadline in the solicitation.

The solicitation does not specify a defined award decision timeline or funding disbursement schedule.

Offerors must include a Schedule outlining prototype delivery, deployment, and phased demonstration.

Where does this funding come from?

Awards will be made leveraging the One Nation Innovation Other Transactional Agreement (OTA) vehicle.

One Nation Innovation is a 501(c)(3) nonprofit intermediary for rapid government acquisition and innovation.

Who is eligible to apply?

The solicitation does not explicitly define eligibility restrictions.

Proposals must include:

• Organization name

• Lead point of contact

• Contact information

Proposals must also address readiness for classified work and ability to operate within government-managed prototype environments.

No additional eligibility limitations are specified in the solicitation.

What companies and projects are likely to win?

Based on the stated evaluation priorities, competitive applicants will demonstrate:

• Ability to mature technologies in pre-requirement environments aligned with DoW priorities

• Demonstrated skill in structured prototyping, experimentation planning, and data collection

• Capacity to produce test-readiness artifacts (safety, certification, interoperability, logistics) at speed and rigor

• Strength in generating bodies of evidence from technical and operational data

• Capability to field a stable, high-competence, cross-functional team that can manage complexity and resolve integration challenges rapidly

Past performance demonstrating rapid deployment or technical advisory support in DoD or dual-use adjacent environments is required .

Are there any restrictions I should know about?

• Proposal length is limited to 10 pages (12pt Arial font).

• A separate cover page is required.

• Required proposal sections are explicitly defined (Technical Overview, Integration Path, ROM Cost Estimate, Past Performance, Schedule, Proposed Personnel Outline).

• Solutions must meet defined mechanical, operational, safety, environmental, and integration criteria.

• Security Requirements: None.

No cost share requirement is specified.

No defined funding cap is specified.

How long will it take me to prepare an application?

The solicitation does not specify preparation timelines. However, the required 10-page proposal must include:

• Technical approach

• Integration readiness

• ROM cost estimate

• Relevant past performance

• Delivery schedule

• Personnel outline

For teams with an existing launcher solution or prototype, preparation time may be shorter. For earlier-stage concepts requiring detailed integration and cost modeling, preparation may require additional internal coordination.

How can BW&CO help?

BW&CO can:

• Translate this JRFA Support challenge into a tightly aligned, evaluator-focused 10-page proposal

• Position your firm against the stated evaluation priorities

• Structure your technical narrative around rapid maturation, experimentation readiness, and transition acceleration

• Develop a compliant ROM cost estimate narrative

• Package past performance to directly address rapid deployment and advisory credibility

• Ensure security positioning is clearly articulated up to TOP SECRET requirements

This is a rolling, biweekly review opportunity. Speed and clarity matter.

How much would BW&CO Charge?

We have both fractional engagements ($250 an hour) and full engagements ($13,000 + 5%) available.

Additional Resources

Review the solicitation here.

OUSW-R&E/PE Unmanned Aerial System (UAS) Launcher Challenge

Below is a brief summary. Please check the full solicitation before applying (link in resources section).

Executive Summary:

The OUSW-R&E/PE Unmanned Aerial System (UAS) Launcher Challenge is an open, rolling prototype opportunity seeking solutions to design and develop a launcher system capable of reliably, safely, and efficiently deploying Group 2–3 UAS platforms.

This is an Open Challenge, meaning submissions remain open for extended durations and are reviewed biweekly. There is no specified application deadline in the solicitation.

Multiple awards may be made. Successful prototypes may transition to follow-on task orders or scaled production. If you have a modular, portable, and field-ready launcher system that meets mechanical, operational, and safety requirements outlined in the Challenge, this is a live pathway into government prototype and potential production work.

How much funding would I receive?

The solicitation does not specify a defined award amount, ceiling, or funding range.

Key funding notes:

• Awards will be made under the One Nation Innovation Other Transactional Agreement (OTA) vehicle.

• The initial award may be augmented with additional prototype or production awards pending successful testing and government need.

• Multiple awards may be made.

Offerors must provide a ROM Cost Estimate covering prototype execution, integration, and optional production.

What could I use the funding for?

Funding supports development and demonstration of a UAS launcher prototype that meets the Challenge objectives.

The launcher must:

Mechanical Requirements

• Withstand repeated launches and environmental stresses

• Allow angle and direction modifications

• Be portable and field-deployable

• Deliver sufficient launch force without damaging the UAS

Operational Requirements

• Enable rapid setup and tear-down

• Include intuitive controls

• Operate on battery, generator, or manual power with backup options

• Function in wind, rain, and temperature extremes

Safety Requirements

• Prevent accidental launches

• Protect operators and UAS

• Include an emergency stop or abort feature

• Adhere to relevant safety standards and regulations

Environmental and Maintenance Requirements

• Use corrosion-resistant materials

• Be easy to inspect and maintain

• Minimize noise and environmental impact

Integration and Future-Proofing

• Integrate with ground control stations and telemetry systems

• Allow software and hardware upgrades

• Include data logging capability

Are there any additional benefits I would receive?

Beyond the initial prototype award:

• Potential for additional prototype or production awards

• Opportunity to transition to follow-on task orders or scaled production

• Engagement through the One Nation Innovation OTA vehicle, designed for rapid government acquisition

What is the timeline to apply and when would I receive funding?

This is an Open Challenge.

• Submissions remain open for extended durations.

• Submissions are generally reviewed biweekly.

• There is no specified application deadline in the solicitation.

The solicitation does not specify a defined award decision timeline or funding disbursement schedule.

Offerors must include a Schedule outlining prototype delivery, deployment, and phased demonstration.

Where does this funding come from?

Awards will be made leveraging the One Nation Innovation Other Transactional Agreement (OTA) vehicle.

One Nation Innovation is a 501(c)(3) nonprofit intermediary for rapid government acquisition and innovation.

Who is eligible to apply?

The solicitation does not explicitly define eligibility restrictions.

Proposals must include:

• Organization name

• Lead point of contact

• Contact information

Proposals must also address readiness for classified work and ability to operate within government-managed prototype environments.

No additional eligibility limitations are specified in the solicitation.

What companies and projects are likely to win?

Awards may be made based on:

• Technical merit

• Delivery readiness

• Mission alignment

Competitive solutions will demonstrate:

• Ability to accommodate Group 2–3 UAS platforms

• Modular, portable design

• Compliance with mechanical, operational, safety, environmental, and integration requirements

• Readiness for integration into government-managed prototype environments

Past performance from DoD or dual-use adjacent work demonstrating rapid deployment or technical advisory support is required.

Are there any restrictions I should know about?

• Proposal length is limited to 10 pages (12pt Arial font).

• A separate cover page is required.

• Required proposal sections are explicitly defined (Technical Overview, Integration Path, ROM Cost Estimate, Past Performance, Schedule, Proposed Personnel Outline).

• Solutions must meet defined mechanical, operational, safety, environmental, and integration criteria.

• Security Requirements: None.

No cost share requirement is specified.

No defined funding cap is specified.

How long will it take me to prepare an application?

The solicitation does not specify preparation timelines. However, the required 10-page proposal must include:

• Technical approach

• Integration readiness

• ROM cost estimate

• Relevant past performance

• Delivery schedule

• Personnel outline

For teams with an existing launcher solution or prototype, preparation time may be shorter. For earlier-stage concepts requiring detailed integration and cost modeling, preparation may require additional internal coordination.

How can BW&CO help?

BW&CO can:

• Translate your existing launcher technology into a government-aligned Technical Overview

• Position your solution against the stated mechanical, operational, and safety criteria

• Structure your Integration Path for prototype environment readiness

• Develop a defensible ROM Cost Estimate narrative

• Highlight relevant DoD or dual-use past performance

• Ensure strict compliance with page limits and required sections

This is a rolling, biweekly review opportunity. Speed and clarity matter.

How much would BW&CO Charge?

We have both fractional engagements ($250 an hour) and full engagements ($13,000 + 5%) available.

Additional Resources

Review the solicitation here.